

DUPONT E I DE NEMOURS & CO

Form 10-Q

October 26, 2010

[Table of Contents](#)

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

## FORM 10-Q

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF  
THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended September 30, 2010

OR

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF  
THE SECURITIES EXCHANGE ACT OF 1934**

Commission File Number 1-815

### **E. I. du Pont de Nemours and Company**

(Exact Name of Registrant as Specified in Its Charter)

**Delaware**

(State or other Jurisdiction of  
Incorporation or Organization)

**51-0014090**

(I.R.S. Employer  
Identification No.)

**1007 Market Street, Wilmington, Delaware 19898**

(Address of Principal Executive Offices)

**(302) 774-1000**

(Registrant's Telephone Number)

## Edgar Filing: DUPONT E I DE NEMOURS & CO - Form 10-Q

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that registrant was required to submit and post such files.) Yes  No

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of large accelerated filer, accelerated filer, and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):

Large Accelerated Filer

Accelerated Filer

Non-Accelerated Filer

Smaller reporting company

Indicate by check mark whether the Registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act). Yes  No

The Registrant had 912,894,000 shares (excludes 87,041,000 shares of treasury stock) of common stock, \$0.30 par value, outstanding at October 15, 2010.

---

Table of Contents**E. I. DU PONT DE NEMOURS AND COMPANY****Table of Contents**

The terms "DuPont" or the "company" as used herein refer to E. I. du Pont de Nemours and Company and its consolidated subsidiaries, or to E. I. du Pont de Nemours and Company, as the context may indicate.

	<b>Page</b>
<b><u>Part I</u></b>	
	<b><u>Financial Information</u></b>
<b><u>Item 1.</u></b>	
	<b><u>Consolidated Financial Statements (Unaudited)</u></b>
	<b><u>Consolidated Income Statements</u></b> 3
	<b><u>Condensed Consolidated Balance Sheets</u></b> 4
	<b><u>Condensed Consolidated Statements of Cash Flows</u></b> 5
	<b><u>Notes to the Consolidated Financial Statements</u></b>
	<b><u>Note 1. Summary of Significant Accounting Policies</u></b> 6
	<b><u>Note 2. Fair Value Measurements</u></b> 6
	<b><u>Note 3. Other Income, Net</u></b> 8
	<b><u>Note 4. Employee Separation / Asset Related Charges, Net</u></b> 8
	<b><u>Note 5. Provision for Income Taxes</u></b> 9
	<b><u>Note 6. Earnings Per Share of Common Stock</u></b> 10
	<b><u>Note 7. Inventories</u></b> 10
	<b><u>Note 8. Goodwill and Other Intangible Assets</u></b> 11
	<b><u>Note 9. Commitments and Contingent Liabilities</u></b> 11
	<b><u>Note 10. Stockholders' Equity</u></b> 19
	<b><u>Note 11. Derivatives and Other Hedging Instruments</u></b> 21
	<b><u>Note 12. Long-Term Employee Benefits</u></b> 26
	<b><u>Note 13. Segment Information</u></b> 27
	<b><u>Note 14. Subsequent Event</u></b> 28
<b><u>Item 2.</u></b>	
	<b><u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u></b> 29
	<b><u>Cautionary Statements About Forward-Looking Statements</u></b> 29
	<b><u>Results of Operations</u></b> 29
	<b><u>Segment Reviews</u></b> 32
	<b><u>Liquidity &amp; Capital Resources</u></b> 35
	<b><u>Contractual Obligations</u></b> 37
	<b><u>PFOA</u></b> 37
<b><u>Item 3.</u></b>	<b><u>Quantitative and Qualitative Disclosures About Market Risk</u></b> 38
<b><u>Item 4.</u></b>	<b><u>Controls and Procedures</u></b> 39
<b><u>Part II</u></b>	
	<b><u>Other Information</u></b>
<b><u>Item 1.</u></b>	<b><u>Legal Proceedings</u></b> 40
<b><u>Item 1A.</u></b>	<b><u>Risk Factors</u></b> 41
<b><u>Item 6.</u></b>	<b><u>Exhibits</u></b> 44
<b><u>Signature</u></b>	<b>45</b>
<b><u>Exhibit Index</u></b>	<b>46</b>



Table of Contents**Part I. Financial Information****Item 1. CONSOLIDATED FINANCIAL STATEMENTS****E. I. du Pont de Nemours and Company****Consolidated Income Statements (Unaudited)***(Dollars in millions, except per share)*

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2010	2009	2010	2009
Net sales	\$ 7,001	\$ 5,961	\$ 24,101	\$ 19,690
Other income, net	66	195	890	824
<b>Total</b>	<b>7,067</b>	<b>6,156</b>	<b>24,991</b>	<b>20,514</b>
Cost of goods sold and other operating charges	5,443	4,560	17,223	14,752
Selling, general and administrative expenses	782	770	2,796	2,584
Research and development expense	409	335	1,178	989
Interest expense	103	100	309	312
Employee separation / asset related charges, net				265
<b>Total</b>	<b>6,737</b>	<b>5,765</b>	<b>21,506</b>	<b>18,902</b>
Income before income taxes	330	391	3,485	1,612
(Benefit from) provision for income taxes	(39)	(23)	811	288
Net income	369	414	2,674	1,324
Less: Net income attributable to noncontrolling interests	2	5	19	10
<b>Net income attributable to DuPont</b>	<b>\$ 367</b>	<b>\$ 409</b>	<b>\$ 2,655</b>	<b>\$ 1,314</b>
Basic earnings per share of common stock	\$ 0.40	\$ 0.45	\$ 2.92	\$ 1.44
Diluted earnings per share of common stock	\$ 0.40	\$ 0.45	\$ 2.89	\$ 1.44
Dividends per share of common stock	\$ 0.41	\$ 0.41	\$ 1.23	\$ 1.23

See Notes to the Consolidated Financial Statements.

Table of Contents**E. I. du Pont de Nemours and Company****Condensed Consolidated Balance Sheets (Unaudited)***(Dollars in millions, except per share)*

	September 30, 2010	December 31, 2009
<b>Assets</b>		
<b>Current assets</b>		
Cash and cash equivalents	\$ 4,088	\$ 4,021
Marketable securities	1,892	2,116
Accounts and notes receivable, net	7,498	5,030
Inventories	5,420	5,380
Prepaid expenses	127	129
Income taxes	564	612
Total current assets	19,589	17,288
Property, plant and equipment, net of accumulated depreciation (September 30, 2010 - \$18,467; December 31, 2009 - \$17,821)	10,976	11,094
Goodwill	2,135	2,137
Other intangible assets	2,407	2,552
Investment in affiliates	1,108	1,014
Other assets	3,703	4,100
<b>Total</b>	<b>\$ 39,918</b>	<b>\$ 38,185</b>
<b>Liabilities and Stockholders Equity</b>		
<b>Current liabilities</b>		
Accounts payable	\$ 3,545	\$ 3,542
Short-term borrowings and capital lease obligations	2,211	1,506
Income taxes	194	154
Other accrued liabilities	3,371	4,188
Total current liabilities	9,321	9,390
Long-term borrowings and capital lease obligations	10,175	9,528
Other liabilities	10,639	11,490
Deferred income taxes	132	126
Total liabilities	30,267	30,534
<b>Commitments and contingent liabilities</b>		
<b>Stockholders equity</b>		
Preferred stock	237	237
Common stock, \$0.30 par value; 1,800,000,000 shares authorized; Issued at September 30, 2010 - 998,029,000; December 31, 2009 - 990,855,000	299	297
Additional paid-in capital	8,763	8,469
Reinvested earnings	12,235	10,710
Accumulated other comprehensive loss	(5,610)	(5,771)
Common stock held in treasury, at cost (87,041,000 shares at September 30, 2010 and December 31, 2009)	(6,727)	(6,727)
Total DuPont stockholders equity	9,197	7,215

Edgar Filing: DUPONT E I DE NEMOURS & CO - Form 10-Q

Noncontrolling interests	454	436
Total equity	9,651	7,651
<b>Total</b>	<b>\$ 39,918</b>	<b>\$ 38,185</b>

See Notes to the Consolidated Financial Statements.

Table of Contents**E. I. du Pont de Nemours and Company****Condensed Consolidated Statements of Cash Flows (Unaudited)***(Dollars in millions)*

	<b>Nine Months Ended September 30,</b>	
	<b>2010</b>	<b>2009</b>
<b>Operating activities</b>		
Net income	\$ 2,674	\$ 1,324
Adjustments to reconcile net income to cash provided by operating activities:		
Depreciation	904	938
Amortization of intangible assets	142	219
Contributions to pension plans	(704)	(243)
Other non-cash charges and credits - net	442	848
Change in operating assets and liabilities - net	(3,423)	(2,163)
Cash provided by operating activities	35	923
<b>Investing activities</b>		
Purchases of property, plant and equipment	(899)	(990)
Investments in affiliates	(71)	(105)
Payments for businesses - net of cash acquired		(12)
Proceeds from sales of assets - net of cash sold	173	51
Net decrease (increase) in short-term financial instruments	201	(800)
Forward exchange contract settlements	396	(757)
Other investing activities - net	(94)	(12)
Cash used for investing activities	(294)	(2,625)
<b>Financing activities</b>		
Dividends paid to stockholders	(1,122)	(1,119)
Net increase in borrowings	1,327	1,408
Proceeds from exercise of stock options	199	
Other financing activities - net	(18)	(14)
Cash provided by financing activities	386	275
Effect of exchange rate changes on cash	(60)	31
<b>Increase (decrease) in cash and cash equivalents</b>	<b>\$ 67</b>	<b>\$ (1,396)</b>
<b>Cash and cash equivalents at beginning of period</b>	<b>4,021</b>	<b>3,645</b>
<b>Cash and cash equivalents at end of period</b>	<b>\$ 4,088</b>	<b>\$ 2,249</b>

See Notes to the Consolidated Financial Statements.





Table of Contents

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

*(Dollars in millions, except per share)*

**Note 1. Summary of Significant Accounting Policies**

**Interim Financial Statements**

The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (GAAP) for interim financial information and the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair statement of the results for interim periods have been included. Results for interim periods should not be considered indicative of results for a full year. These interim Consolidated Financial Statements should be read in conjunction with the Consolidated Financial Statements and Notes thereto contained in the company's Annual Report on Form 10-K for the year ended December 31, 2009, collectively referred to as the 2009 Annual Report. The Consolidated Financial Statements include the accounts of the company and all of its subsidiaries in which a controlling interest is maintained, as well as variable interest entities in which DuPont is considered the primary beneficiary. Certain reclassifications of prior year's data have been made to conform to current year classifications.

**Recent Accounting Pronouncements**

The Financial Accounting Standards Board (FASB) issued authoritative guidance on accounting for transfers of financial assets, which is applied to financial asset transfers on or after the effective date, which is January 1, 2010 for the company's financial statements. The new requirement limits the circumstances in which a financial asset may be de-recognized when the transferor has not transferred the entire financial asset or has continuing involvement with the transferred asset. The concept of a qualifying special-purpose entity, which had previously facilitated sale accounting for certain asset transfers, is removed by the new requirement. The adoption of this guidance did not have a material effect on the company's financial position or results of operations.

The FASB issued authoritative guidance on accounting for variable interest entities, which is effective for reporting periods beginning after November 15, 2009. The amendments change the process for how an enterprise determines which party consolidates a variable interest entity (VIE) to a primarily qualitative analysis. The party that consolidates the VIE (the primary beneficiary) is defined as the party with (1) the power to direct activities of the VIE that most significantly affect the VIE's economic performance and (2) the obligation to absorb losses of the VIE or the right to receive benefits from the VIE. Upon adoption, reporting enterprises must reconsider their conclusions on whether an entity should be consolidated. The adoption of this guidance did not have a material effect on the company's financial position or results of operations.

**Note 2. Fair Value Measurements**

## Edgar Filing: DUPONT E I DE NEMOURS & CO - Form 10-Q

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The company uses the following valuation techniques to measure fair value for its financial assets and financial liabilities:

- Level 1      Quoted market prices in active markets for identical assets or liabilities;
- Level 2      Significant other observable inputs (e.g. quoted prices for similar items in active markets, quoted prices for identical or similar items in markets that are not active, inputs other than quoted prices that are observable such as interest rate and yield curves, and market-corroborated inputs);
- Level 3      Unobservable inputs for the asset or liability, which are valued based on management's estimates of assumptions that market participants would use in pricing the asset or liability.

Table of Contents**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS***(Dollars in millions, except per share)*

The company has determined that its financial assets and liabilities are level 1 and level 2 in the fair value hierarchy. At September 30, 2010, the following financial assets and financial liabilities were measured at fair value on a recurring basis using the type of inputs shown:

	September 30, 2010	Fair Value Measurements at September 30, 2010 Using	
		Level 1 Inputs	Level 2 Inputs
<b>Financial assets</b>			
Derivatives	\$ 96	\$	\$ 96
Available-for-sale securities	18	18	
	\$ 114	\$ 18	\$ 96
<b>Financial liabilities</b>			
Derivatives	\$ 323	\$	\$ 323

At December 31, 2009, the following financial assets and liabilities were measured at fair value on a recurring basis using the type of inputs shown:

	December 31, 2009	Fair Value Measurements at December 31, 2009 Using	
		Level 1 Inputs	Level 2 Inputs
<b>Financial assets</b>			
Derivatives	\$ 128	\$	\$ 128
Available-for-sale securities	27	27	
	\$ 155	\$ 27	\$ 128
<b>Financial liabilities</b>			
Derivatives	\$ 132	\$	\$ 132

The estimated fair value of the company's outstanding debt, including interest rate financial instruments, based on quoted market prices for the same or similar issues or on current rates offered to the company for debt of the same remaining maturities, was \$13,600 and \$11,600 as of September 30, 2010 and December 31, 2009, respectively. The carrying value of debt was approximately \$12,400 and \$11,000 as of September 30, 2010 and December 31, 2009, respectively.

See Note 22, Long-Term Employee Benefits to the company's 2009 Annual Report for information regarding the company's pension assets measured at fair value on a recurring basis.



Table of Contents**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS***(Dollars in millions, except per share)***Note 3. Other Income, Net**

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2010	2009	2010	2009
Cozaar®/Hyzaar® income	\$ 109	\$ 264	\$ 397	\$ 786
Royalty income	36	20	89	71
Interest income	28	22	68	68
Equity in earnings of affiliates, excluding exchange gains/losses	33	15	119	49
Net gains on sales of assets	1	2	96	43
Net exchange losses (1)	(160)	(128)	(25)	(202)
Miscellaneous income and expenses, net (2)	19		146	9
<b>Total</b>	<b>\$ 66</b>	<b>\$ 195</b>	<b>\$ 890</b>	<b>\$ 824</b>

(1) The company routinely uses forward exchange contracts to offset its net exposures, by currency, related to its foreign currency-denominated monetary assets and liabilities. The objective of this program is to maintain an approximately balanced position in foreign currencies in order to minimize, on an after-tax basis, the effects of exchange rate changes on net monetary asset positions. The net pre-tax exchange gains and losses are partially offset by the associated tax impact.

(2) Miscellaneous income and expenses, net, includes interest items, insurance recoveries and other items.

**Note 4. Employee Separation / Asset Related Charges, Net**

At September 30, 2010, total liabilities relating to prior restructuring activities were \$120. A complete discussion of restructuring initiatives is included in the company's 2009 Annual Report in Note 5, Employee Separation / Asset Related Charges, Net.

**2009 Restructuring Program**

Account balances and activity for the 2009 restructuring program are summarized below:

Edgar Filing: DUPONT E I DE NEMOURS & CO - Form 10-Q

	Employee Separation Costs		Other Non- personnel Charges(1)		Total
Balance at December 31, 2009	\$ 150	\$	24	\$	174
Payments	(67)(2)		(20)		(87)
Net translation adjustment	(5)				(5)
Balance at September 30, 2010	\$ 78	\$	4	\$	82

---

(1) Other non-personnel charges consist of contractual obligation costs.

(2) Payments to U.S. based employees are generally paid over a period of time not to exceed twelve months.

There were \$67 of employee separation cash payments related to the 2009 restructuring program during the nine months ended September 30, 2010. As of September 30, 2010, approximately 1,300 employees have been separated related to the 2009 restructuring program. The company expects this initiative to be substantially complete by the end of 2010 with payments continuing into 2011.

Table of Contents**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS***(Dollars in millions, except per share)***2008 Restructuring Program**

The account balances and activity for the company's 2008 global restructuring program are as follows:

	<b>Employee Separation Costs</b>		<b>Other Non- personnel Charges(1)</b>		<b>Total</b>
Balance at December 31, 2009	\$ 105	\$	9	\$	114
Payments	(73)(2)		(5)		(78)
Net translation adjustment	(7)				(7)
Balance at September 30, 2010	\$ 25	\$	4	\$	29

(1) Other non-personnel charges consist of contractual obligation costs.

(2) Payments to employees of non-U.S. based subsidiaries are generally paid in lump sum amounts and are based on years of service. Payments to U.S. based employees are generally paid over a period of time not to exceed twelve months.

There were \$73 of employee separation cash payments related to the 2008 restructuring program during the nine months ended September 30, 2010. As of September 30, 2010, approximately 1,800 employees have been separated related to the 2008 restructuring program. The program and related payments are expected to be substantially complete by the end of 2010.

**Note 5. Provision for Income Taxes**

In the third quarter 2010, the company recorded a tax benefit of \$39, including \$157 of tax benefit primarily associated with the company's policy of hedging the foreign currency-denominated monetary assets and liabilities of its operations.

For year-to-date 2010, the company recorded a tax provision of \$811, including \$54 of tax expense primarily associated with the company's policy of hedging the foreign currency-denominated monetary assets and liabilities of its operations and \$49 net tax benefit related to the adjustment of income tax accruals associated with settlements of prior year tax contingencies.



## Edgar Filing: DUPONT E I DE NEMOURS & CO - Form 10-Q

In the third quarter 2009, the company recorded a tax benefit of \$23, including \$117 of tax benefit primarily associated with the company's policy of hedging the foreign currency-denominated monetary assets and liabilities of its operations.

For year-to-date 2009, the company recorded a tax provision of \$288, including \$117 of tax benefit primarily associated with the company's policy of hedging the foreign currency-denominated monetary assets and liabilities of its operations, \$91 net tax benefit related to 2008 and 2009 restructuring and \$17 net tax expense related to the hurricane adjustments.

Each year the company files hundreds of tax returns in the various national, state and local income taxing jurisdictions in which it operates. These tax returns are subject to examination and possible challenge by the taxing authorities. Positions challenged by the taxing authorities may be settled or appealed by the company. As a result, there is an uncertainty in income taxes recognized in the company's financial statements in accordance with accounting for income taxes and accounting for uncertainty in income taxes. It is reasonably possible that changes to the company's global unrecognized tax benefits could be significant, however, due to the uncertainty regarding the timing of completion of audits and possible outcomes, a current estimate of the range of increases or decreases that may occur within the next twelve months cannot be made.

Table of Contents**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS***(Dollars in millions, except per share)***Note 6. Earnings Per Share of Common Stock**

Set forth below is a reconciliation of the numerator and denominator for basic and diluted earnings per share calculations for the periods indicated:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2010	2009	2010	2009
<b>Numerator:</b>				
Net income attributable to DuPont	\$ 367	\$ 409	\$ 2,655	\$ 1,314
Preferred dividends	(3)	(3)	(8)	(8)
Net income available to DuPont common stockholders	\$ 364	\$ 406	\$ 2,647	\$ 1,306
<b>Denominator:</b>				
Weighted-average number of common shares - Basic	908,366,000	904,615,000	906,991,000	904,350,000
Dilutive effect of the company's employee compensation plans	10,134,000	5,676,000	7,996,000	3,646,000
Weighted-average number of common shares - Diluted	918,500,000	910,291,000	914,987,000	907,996,000

The following average number of stock options were antidilutive, and therefore, were not included in the diluted earnings per share calculations:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2010	2009	2010	2009
Average Number of Stock Options	47,108,000	70,137,000	56,845,000	73,949,000

**Note 7. Inventories**

	September 30, 2010	December 31, 2009
Finished products	\$ 3,277	\$ 2,893

Edgar Filing: DUPONT E I DE NEMOURS & CO - Form 10-Q

Semifinished products		1,862		2,231
Raw materials and supplies		915		872
		6,054		5,996
Adjustment of inventories to a last-in, first-out (LIFO) basis		(634)		(616)
Total	\$	5,420	\$	5,380

Table of Contents

## NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

*(Dollars in millions, except per share)***Note 8. Goodwill and Other Intangible Assets**

There were no significant changes in goodwill for the nine month period ended September 30, 2010.

The gross carrying amounts and accumulated amortization of other intangible assets by major class are as follows:

	September 30, 2010			December 31, 2009		
	Gross	Accumulated Amortization	Net	Gross	Accumulated Amortization	Net
Intangible assets subject to amortization (Definite-lived):						
Purchased and licensed						
technology	\$ 1,621	\$ (809)	\$ 812	\$ 1,622	\$ (716)	\$ 906
Patents	154	(58)	96	169	(57)	112
Trademarks	57	(21)	36	62	(22)	40
Other (1)	584	(272)	312	642	(302)	340
	2,416	(1,160)	1,256	2,495	(1,097)	1,398
Intangible assets not subject to amortization (Indefinite-lived):						
Trademarks / tradenames	176		176	179		179
Pioneer germplasm (2)	975		975	975		975
	1,151		1,151	1,154		1,154
<b>Total</b>	<b>\$ 3,567</b>	<b>\$ (1,160)</b>	<b>\$ 2,407</b>	<b>\$ 3,649</b>	<b>\$ (1,097)</b>	<b>\$ 2,552</b>

(1) Primarily consists of sales and grower networks, customer lists, marketing and manufacturing alliances and noncompetition agreements.

(2) Pioneer germplasm is the pool of genetic source material and body of knowledge gained from the development and delivery stage of plant breeding. The company recognized germplasm as an intangible asset upon the acquisition of Pioneer. This intangible asset is expected to contribute to cash flows beyond the foreseeable future and there are no legal, regulatory, contractual, or other factors which limit its useful life.

The aggregate pre-tax amortization expense for definitive-lived intangible assets was \$32 and \$142 for the three and nine month periods ended September 30, 2010, respectively, and \$52 and \$219 for the three and nine month periods ended September 30, 2009, respectively. The estimated aggregate pre-tax amortization expense for 2010 and each of the next five years is approximately \$176, \$180, \$184, \$188, \$182 and

\$149.

**Note 9. Commitments and Contingent Liabilities**

**Guarantees**

*Product Warranty Liability*

The company warrants that its products meet standard specifications. The company's product warranty liability was \$17 as of September 30, 2010 and December 31, 2009. Estimates for warranty costs are based on historical claims experience.

*Indemnifications*

In connection with acquisitions and divestitures, the company has indemnified respective parties against certain liabilities that may arise in connection with these transactions and business activities prior to the completion of the transaction. The term of these indemnifications, which typically pertain to environmental, tax and product liabilities, is generally indefinite. In addition, the company indemnifies its duly elected or

Table of Contents

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

*(Dollars in millions, except per share)*

appointed directors and officers to the fullest extent permitted by Delaware law, against liabilities incurred as a result of their activities for the company, such as adverse judgments relating to litigation matters. If the indemnified party were to incur a liability or have a liability increase as a result of a successful claim, pursuant to the terms of the indemnification, the company would be required to reimburse the indemnified party. The maximum amount of potential future payments is generally unlimited. The carrying amount recorded for all indemnifications as of September 30, 2010 and December 31, 2009 was \$99 and \$100, respectively. Although it is reasonably possible that future payments may exceed amounts accrued, due to the nature of indemnified items, it is not possible to make a reasonable estimate of the maximum potential loss or range of loss. No assets are held as collateral and no specific recourse provisions exist.

In connection with the 2004 sale of the majority of the net assets of Textiles and Interiors, the company indemnified the purchasers, subsidiaries of Koch Industries, Inc. (INVISTA), against certain liabilities primarily related to taxes, legal and environmental matters and other representations and warranties under the Purchase and Sale Agreement. The estimated fair value of the indemnity obligations under the Purchase and Sale Agreement was \$70 and was included in the indemnifications balance of \$99 at September 30, 2010. Under the Purchase and Sale Agreement, the company's total indemnification obligation for the majority of the representations and warranties cannot exceed \$1,400. The other indemnities are not subject to this limit. In March 2008, INVISTA filed suit in the Southern District of New York alleging that certain representations and warranties in the Purchase and Sale Agreement were breached and, therefore, that DuPont is obligated to indemnify it. DuPont disagrees with the extent and value of INVISTA's claims. DuPont has not changed its estimate of its total indemnification obligation under the Purchase and Sale Agreement as a result of the lawsuit.

*Obligations for Equity Affiliates & Others*

The company has directly guaranteed various debt obligations under agreements with third parties related to equity affiliates, customers, suppliers and other affiliated and unaffiliated companies. At September 30, 2010 and December 31, 2009, the company had directly guaranteed \$501 and \$684, respectively, of such obligations. In addition, the company had \$16 and \$119 relating to guarantees of historical obligations for divested subsidiaries as of September 30, 2010 and December 31, 2009, respectively. The \$103 decrease for the guarantees of historical obligations for divested subsidiaries was due to the termination of the guarantees for Consolidation Coal Sales Company in September 2010. These amounts represent the maximum potential amount of future (undiscounted) payments that the company could be required to make under the guarantees. The company would be required to perform on these guarantees in the event of default by the guaranteed party.

The company assesses the payment/performance risk by assigning default rates based on the duration of the guarantees. These default rates are assigned based on the external credit rating of the counterparty or through internal credit analysis and historical default history for counterparties that do not have published credit ratings. For counterparties without an external rating or available credit history, a cumulative average default rate is used.

At September 30, 2010 and December 31, 2009, a liability of \$116 and \$146, respectively, was recorded for these obligations, representing the amount of payment/performance risk for which the company deems probable. This liability is principally related to obligations of the company's polyester films joint venture, which are guaranteed by the company.



Table of Contents**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS***(Dollars in millions, except per share)*

In certain cases, the company has recourse to assets held as collateral, as well as personal guarantees from customers and suppliers. Assuming liquidation, these assets are estimated to cover approximately 37 percent of the \$230 of guaranteed obligations of customers and suppliers. Set forth below are the company's guaranteed obligations at September 30, 2010:

	<b>Short- Term</b>		<b>Long- Term</b>		<b>Total</b>
Obligations for customers, suppliers and other affiliated and unaffiliated companies(1), (2):					
Bank borrowings (terms up to 5 years)	\$ 322	\$	133	\$	455
Obligations for equity affiliates(2):					
Bank borrowings (terms up to 3 years)	7		15		22
Leases on equipment and facilities (terms less than 1 year)	1				1
Revenue bonds (terms up to 5 years)			23		23
Total obligations for customers, suppliers, other affiliated and unaffiliated companies, and equity affiliates	\$ 330	\$	171	\$	501
Obligations for divested subsidiaries(3):					
Conoco (terms up to 16 years)			16		16
Total obligations for divested subsidiaries			16		16
	\$ 330	\$	187	\$	517

- 
- (1) Existing guarantees for customers, suppliers, and other unaffiliated companies arose as part of contractual agreements.
- (2) Existing guarantees for equity affiliates and other affiliated companies arose for liquidity needs in normal operations.
- (3) The company has guaranteed certain obligations and liabilities related to a divested subsidiary, Conoco, which has indemnified the company for any liabilities the company may incur pursuant to these guarantees.

**Litigation**PFOA

At September 30, 2010, DuPont has accruals of \$19 related to the PFOA matters described below.

**Regulatory and Environmental Actions**



## Edgar Filing: DUPONT E I DE NEMOURS & CO - Form 10-Q

In January 2009, the U.S. Environmental Protection Agency (EPA) issued a national Provisional Health Advisory for PFOA of 0.4 parts per billion (ppb) in drinking water. In March 2009, EPA and DuPont entered an Order on Consent under the Safe Drinking Water Act (SDWA) reflecting an action level of 0.40 ppb. Under the terms of the 2009 consent order, DuPont will conduct surveys, sampling and analytical testing in the area around its Washington Works site located in Parkersburg, West Virginia. If tests indicate the presence of PFOA, (collectively, perfluorooctanoic acids and its salts, including the ammonium salt), in drinking water at 0.40 ppb or greater, the company will offer treatment or an alternative supply of drinking water. The 2009 consent order supersedes the November 2006 Order on Consent between DuPont and EPA which established a precautionary interim screening level for PFOA of 0.50 ppb in drinking water sources in the area around the Washington Works site. All of DuPont's remaining obligations under the 2006 consent order have been incorporated into the 2009 consent order.

In late 2005, DuPont and EPA entered into a Memorandum of Understanding (EPA MOU) that required DuPont to monitor PFOA in the soil, air, water and biota around the Washington Works site. The required third party peer review of the data generated in the monitoring process has been completed. EPA issued its final report in September 2009 to which DuPont responded. EPA provided comments on DuPont's response in the first quarter 2010. EPA and the company are discussing a plan for further monitoring under the MOU.

In late 2009, DuPont received an Information Request from EPA under the Clean Water Act (CWA) regarding previously reported historic disposal practices for waste generated by the Washington Works site that may contain PFOA. In December 2009, a similar request was made under the Resource

Table of Contents

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

*(Dollars in millions, except per share)*

Conservation and Recovery Act (RCRA) regarding the Chambers Works site in Deepwater, New Jersey. DuPont has responded to these requests.

In 2009, DuPont entered into a voluntary agreement with the New Jersey Department of Environmental Protection (NJDEP), to sample private wells within a two-mile radius of its Chambers Works site in Deepwater, New Jersey for the presence of PFOA and treat any wells with PFOA above 0.40 ppb. DuPont has completed its obligations under the agreement and is treating one well.

***EPA Administrative Complaints***

In July and December 2004, EPA filed administrative complaints against DuPont alleging that the company failed to comply with the technical reporting requirements of the Toxic Substances Control Act (TSCA) and the RCRA regarding PFOA. Under a 2005 agreement settling the matter, the company paid civil fines of \$10.25 and will complete two Supplemental Environmental Projects at a total cost of \$6.25.

***Civil Actions: Drinking Water***

In August 2001, a class action, captioned Leach v. DuPont, was filed in West Virginia state court against DuPont and the Lubeck Public Service District. DuPont uses PFOA as a processing aid to manufacture fluoropolymer resins and dispersions at various sites around the world including its Washington Works plant in West Virginia. The complaint alleged that residents living near the Washington Works facility had suffered, or may suffer, deleterious health effects from exposure to PFOA in drinking water. The relief sought included damages for medical monitoring, diminution of property values and punitive damages plus injunctive relief to stop releases of PFOA. DuPont and attorneys for the class reached a settlement agreement in 2004 and as a result, the company established accruals of \$108 in 2004. The agreement was approved by the Wood County Circuit Court on February 28, 2005 after a fairness hearing. The settlement binds a class of approximately 80,000 residents. As defined by the court, the class includes those individuals who have consumed, for at least one year, water containing 0.05 ppb or greater of PFOA from any of six designated public water sources or from sole source private wells.

In July 2005, the company paid the plaintiffs' attorneys' fees and expenses of \$23 and made a payment of \$70, which class counsel has designated to fund a community health project. The company is also funding a series of health studies by an independent science panel of experts in the communities exposed to PFOA to evaluate available scientific evidence on whether any probable link exists between exposure to PFOA and human disease. The company expects the independent science panel to complete these health studies between 2009 and year-end 2011 at a total estimated cost of \$32, of which \$5 was originally placed in an interest-bearing escrow account. In addition, the company is providing state-of-the-art water treatment systems designed to reduce the level of PFOA in water to six area water districts, including the Little Hocking Water Association (LHWA), until the science panel determines that PFOA does not cause disease or until applicable water standards can be met without such treatment. All of the water treatment systems are operating.

## Edgar Filing: DUPONT E I DE NEMOURS & CO - Form 10-Q

The settlement resulted in the dismissal of all claims asserted in the lawsuit except for personal injury claims. If the independent science panel concludes that no probable link exists between exposure to PFOA and any diseases, then the settlement would also resolve personal injury claims. If it concludes that a probable link does exist between exposure to PFOA and any diseases, then DuPont would also fund up to \$235 for a medical monitoring program to pay for such medical testing. In this event, plaintiffs would retain their right to pursue personal injury claims. All other claims in the lawsuit would remain dismissed by the settlement. DuPont believes that it is remote that the panel will find a probable link. Therefore, at September 30, 2010, the company had not established any accruals related to medical

Table of Contents

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

*(Dollars in millions, except per share)*

monitoring or personal injury claims. However, there can be no assurance as to what the independent science panel will conclude.

In September 2007, LHWA refiled the suit it originally filed in Ohio state court and voluntarily dismissed in 2006. The suit claims that perfluorinated compounds, including PFOA, allegedly released from the Washington Works plant contaminated LHWA's well fields and underlying aquifer. In November 2009, LHWA sued DuPont in Ohio federal court alleging among other claims imminent and substantial endangerment to health and or the environment under RCRA based on detection of PFOA in its wells. LHWA seeks a variety of relief in both cases including compensatory and punitive damages, and an injunction requiring DuPont to provide a new pristine well field and the infrastructure to deliver it.

In the third quarter 2009, Emerald Coast Utilities Authority, owner and operator of public drinking water systems in Pensacola, Florida and nearby areas, filed suit against several defendants including the company alleging water contamination from PFOA and perfluorooctane sulfonate (PFOS). The case, originally filed in Florida state court, was removed to federal court in the fourth quarter 2009. DuPont does not have any facilities in the water district served by the Emerald Coast Utilities Authority that manufacture or use PFOA. DuPont does not and has not manufactured PFOS and does not use the compound in its processes. The complaint seeks testing, treatment, remediation and monitoring. In the third quarter 2010, the court granted defendants' motion for summary judgment and dismissed the case. Plaintiffs must decide whether to appeal by the end of October 2010.

In the second quarter 2006, three purported class actions were filed alleging that drinking water had been contaminated by PFOA in excess of 0.05 ppb due to alleged releases from certain DuPont plants. One of these cases was filed in West Virginia state court by three individual plaintiffs on behalf of customers of the Parkersburg City Water District, but was removed on DuPont's motion to the U.S. District Court for the Southern District of West Virginia. In September 2008, the U.S. District Court ruled that the case could not proceed as a class action. Plaintiffs' appeal of the ruling was denied. In the second quarter 2009, the plaintiffs added a claim based on public nuisance and moved for again class certification. In the third quarter 2009, the court granted summary judgment in DuPont's favor dismissing all claims brought by the three plaintiffs, including public nuisance and class certification, except for medical monitoring. In the fourth quarter 2009, plaintiffs voluntarily dismissed the medical monitoring claims. The court entered final judgment for DuPont in January 2010. In the first quarter 2010, plaintiffs appealed the final judgment to the U.S. Court of Appeals for the Fourth Circuit. A ruling is expected in 2011.

The other two purported class actions were filed in New Jersey. One was filed in federal court on behalf of individuals who allegedly drank water contaminated by releases from DuPont's Chambers Works plant in Deepwater, New Jersey. The second was filed in state court on behalf of customers serviced primarily by the Pennsville Township Water Department and was removed to New Jersey federal district court on DuPont's motion. The New Jersey cases have been combined for purposes of discovery and the complaints have been amended to allege that drinking water had been contaminated by PFOA in excess of 0.04 ppb. In December 2008, the court denied class action status in both cases, but ordered additional briefing on certain issues. In October 2009, the court granted class certification for certain sub-classes regarding public and private nuisance claims, while denying class certification for all other claims. The court also certified a legal question related to strict liability. In April 2010, the court allowed plaintiffs in both cases to add a claim under RCRA alleging imminent and substantial endangerment to health and or the environment. The court will set a trial date upon resolution of motions filed in the third and fourth quarter 2010. Pending further rulings by the court, the remedies sought by the class are expected to include abatement of the alleged nuisance, e.g. reduction of PFOA in drinking water to less than 0.04 ppb, and monetary damages for alleged property diminution.

DuPont denies the claims alleged in these civil drinking water actions and is defending itself vigorously.

Table of Contents

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

*(Dollars in millions, except per share)*

Elastomers Antitrust Matters

In 2002, the U.S., Canadian and European Union (EU) antitrust authorities began investigating companies competing in the synthetic rubber market including DuPont Dow Elastomers, LLC (DDE), a joint venture between The Dow Chemical Company (Dow) and DuPont. DDE became a wholly owned subsidiary of DuPont and was renamed DuPont Performance Elastomers, LLC (DPE) in 2005. In April 2004, DuPont and Dow entered into a series of agreements under which DuPont obtained complete control over directing DDE's response to these investigations and the related litigation and DuPont agreed to a disproportionate share of the venture's liabilities and costs related to these matters. Consequently, DuPont bears any potential liabilities and costs up to the initial \$150. Dow is obligated to indemnify DuPont for up to \$72.5 by paying 15 to 30 percent toward liabilities and costs in excess of \$150.

DDE entered a 2005 plea agreement with the U.S. Department of Justice that included a fine of \$84. The company elected to pay the fine in six equal installments; the last installment was paid during the first quarter 2010. In 2007, DPE pled guilty to conspiring to fix prices in the Canadian synthetic rubber market and paid a fine of CDN \$4, approximately \$3.8 USD.

In December 2007, the EU antitrust authorities imposed fines against DPE, Dow and DuPont totaling EURO 59.25 (\$90.9 USD). DuPont provisionally paid the fines in 2008 prior to appealing the EU decision. The EU antitrust authorities subsequently imposed an incremental fine of EURO 4.425 (\$6.5 USD) on Dow which was provisionally paid in 2008.

The company has resolved all criminal antitrust allegations involving the synthetic rubber market against it made by U.S., Canadian, and, pending resolution of the company's appeal, the EU antitrust authorities. At September 30, 2010, the company does not have an accrual related to this matter.

Benlate®

In 1991, DuPont began receiving claims by growers that use of Benlate® 50 DF fungicide had caused crop damage. DuPont has since been served with thousands of lawsuits, most of which have been disposed of through trial, dismissal or settlement. The status of Benlate® cases is indicated in the table below:

**Number of Cases**

Balance at December 31, 2009	13
Filed	
Resolved	

Edgar Filing: DUPONT E I DE NEMOURS & CO - Form 10-Q

Balance at March 31, 2010	13
Filed	
Resolved	(1)
Balance at June 30, 2010	12
Filed	
Resolved	
Balance at September 30, 2010	12

At September 30, 2010, there were twelve cases pending in Florida courts, nine of which involve allegations that Benlate® caused crop damage. At the 2006 trial of two cases involving twenty-seven Costa Rican fern growers, the plaintiffs sought damages in the range of \$270 to \$400. A \$56 judgment was rendered against the company, but was reduced to \$24 on DuPont's motion. In the fourth quarter 2009, on DuPont's motion, the judgment was reversed, vacated and the cases were remanded to be tried separately. Plaintiffs will likely seek further appellate review. Two other crop cases are scheduled for trial in 2011.

Table of Contents

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

*(Dollars in millions, except per share)*

Two cases alleging damage to shrimping operations were decided in DuPont's favor on appeal, but in September 2007, the judge granted plaintiffs' motion for new trial thus reinstating the cases. Previously, these plaintiffs had been awarded unspecified attorneys' fees as sanctions for alleged discovery abuses by DuPont. In June 2009, the judge issued an order striking DuPont's pleadings and entering a default judgment against the company as to liability and causation. Therefore, only the issue of damages would have been tried in both cases. Shortly before the trial of the first case was to begin in August 2010, the parties agreed to arbitrate the issue of damages for both cases. The arbitration is scheduled for the fourth quarter 2010. The arbitrator's award will be binding on the parties.

In January 2009, a case was filed in Florida state court claiming that plaintiff's exposure to Benlate® allegedly contaminated with other fungicides and herbicides, caused plaintiff's kidney cancer and pancreatic and brain tumors. The case was tried to a verdict in September 2010 in federal court, to which it had been removed on DuPont's motion, and the jury unanimously rejected allegations that exposure to Benlate® caused plaintiff's diseases. Plaintiff may appeal the verdict.

The company does not believe that Benlate® caused the damages alleged in each of these cases and denies the allegations of fraud and misconduct. The company continues to defend itself in ongoing matters. As of September 30, 2010, the company has incurred costs and expenses of approximately \$2,000 associated with these matters, but does not expect additional significant costs or expenses associated with the remaining 12 cases. The company has recovered approximately \$275 of its costs and expenses through insurance and does not expect additional insurance recoveries, if any, to be significant. As a result of the agreement to enter binding arbitration, the company increased its accruals related to Benlate® in the third quarter 2010. At September 30, 2010, the company has accruals of \$15.1 related to Benlate®.

Spelter, West Virginia

In September 2006, a West Virginia state court certified a class action captioned Perrine v DuPont, against DuPont that seeks relief including the provision of remediation services and property value diminution damages for 7,000 residential properties in the vicinity of a closed zinc smelter in Spelter, West Virginia. The action also seeks medical monitoring for an undetermined number of residents in the class area. The smelter was owned and operated by at least three companies between 1910 and 2001, including DuPont between 1928 and 1950. DuPont performed remedial measures at the request of EPA in the late 1990s and in 2001 repurchased the site to facilitate and complete the remediation. The fall 2007 trial was conducted in four phases: liability, medical monitoring, property and punitive damages. The jury found against DuPont in all four phases awarding \$55.5 for property remediation and \$196.2 in punitive damages. In post trial motions, the court adopted the plaintiffs' forty-year medical monitoring plan estimated by plaintiffs to cost \$130 and granted plaintiffs' attorneys legal fees of \$127 plus \$8 in expenses based on and included in the total jury award.

In June 2008, DuPont filed its petitions for appeal with the West Virginia Supreme Court (the Court) seeking review of a number of issues associated with the trial court's decisions before, during and after the trial. The Court issued its decision on March 26, 2010, affirming in part and reversing in part the trial court's decision.



## Edgar Filing: DUPONT E I DE NEMOURS & CO - Form 10-Q

The Court conditionally affirmed the verdict, but reduced punitive damages to \$97.7 and gave plaintiffs the option to re-try punitive damages. In July 2010, plaintiffs accepted the reduced punitive damage award and, as a result, the issue of punitive damages will not be re-tried.

Also in its March 2010 decision, the Court reversed the trial court's order granting summary judgment to the adult plaintiffs on the issue of statute of limitations and ordered a new jury trial on the sole issue of when the plaintiffs possessed requisite knowledge to trigger the running of the statute. The trial has been set for March 7, 2011. If the jury determines that the adult plaintiffs had or should have had requisite knowledge more than 2 years prior to filing their case, then the trial court must set aside the verdict and render judgment in DuPont's favor. DuPont does not have a statute of limitations defense as to medical monitoring claims for plaintiffs who were minors when their claims accrued.

Table of Contents

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

*(Dollars in millions, except per share)*

As of September 30, 2010, the company had recorded accruals of \$55, although given the uncertainties inherent in litigation there can be no assurance as to the final outcome.

*General*

The company is subject to various lawsuits and claims arising out of the normal course of its business. These lawsuits and claims include actions based on alleged exposures to products, intellectual property and environmental matters and contract and antitrust claims. Management has noted a nationwide trend in purported class actions against chemical manufacturers generally seeking relief such as medical monitoring, property damages, off-site remediation and punitive damages arising from alleged environmental torts without claiming present personal injuries. Such cases may allege contamination from unregulated substances or remediated sites. The company also has noted a trend in public and private nuisance suits being filed on behalf of states, counties, cities and utilities alleging harm to the general public. Although it is not possible to predict the outcome of these various lawsuits and claims, management does not anticipate they will have a materially adverse effect on the company's consolidated financial position or liquidity. However, the ultimate liabilities may be significant to results of operations in the period recognized. The company accrues for contingencies when the information available indicates that it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated.

*Environmental*

The company is also subject to contingencies pursuant to environmental laws and regulations that in the future may require the company to take further action to correct the effects on the environment of prior disposal practices or releases of chemical or petroleum substances by the company or other parties. The company accrues for environmental remediation activities consistent with the policy set forth in Note 1 in the company's 2009 Annual Report. Much of this liability results from the Comprehensive Environmental Response, Compensation and Liability Act (CERCLA, often referred to as Superfund), RCRA and similar state and global laws. These laws require the company to undertake certain investigative and remedial activities at sites where the company conducts or once conducted operations or at sites where company-generated waste was disposed. The accrual also includes estimated costs related to a number of sites identified by the company for which it is probable that environmental remediation will be required, but which are not currently the subject of enforcement activities.

Remediation activities vary substantially in duration and cost from site to site. These activities, and their associated costs, depend on the mix of unique site characteristics, evolving remediation technologies, diverse regulatory agencies and enforcement policies, as well as the presence or absence of potentially responsible parties. At September 30, 2010, the Condensed Consolidated Balance Sheets included a liability of \$416, relating to these matters and, in management's opinion, is appropriate based on existing facts and circumstances. The average time frame, over which the accrued or presently unrecognized amounts may be paid, based on past history, is estimated to be 15-20 years. Considerable uncertainty exists with respect to these costs and, under adverse changes in circumstances, potential liability may range up to two to three times the amount accrued as of September 30, 2010.

*Other*

The company has various purchase commitments incident to the ordinary conduct of business. In the aggregate, such commitments are not at prices in excess of current market.

Table of Contents

## NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

*(Dollars in millions, except per share)***Note 10. Stockholders Equity**

A summary of the changes in equity for the three and nine months ended September 30, 2010 and 2009 is provided below:

Consolidated Changes in Equity for the Three Months Ended September 30, 2010	Total	Comprehensive Income	Preferred Stock	Common Stock	Additional Paid-in- Capital	Reinvested Earnings	Accumulated Other Comprehensive Loss	Treasury Stock	Noncontrolling Interests
Beginning balance	\$ 9,276		\$ 237	\$ 298	\$ 8,569	\$ 12,245	\$ (5,796)	\$ (6,727)	\$ 450
Comprehensive income:									
Net income	369	\$ 369				367			2
Other comprehensive income (loss), net of tax:									
Cumulative translation adjustment	108	108					106		2
Net revaluation and clearance of cash flow hedges to earnings	1	1					1		
Pension benefit plans	86	86					86		
Other benefit plans	(8)	(8)					(8)		
Net unrealized gain on securities	1	1					1		
Other comprehensive income	188	188							
Comprehensive income	557	\$ 557(1)							
Common dividends	(374)					(374)			
Preferred dividends	(3)					(3)			
Common stock issued - compensation plans	195			1	194				
<b>Total Equity as of September 30, 2010</b>	<b>\$ 9,651</b>		<b>\$ 237</b>	<b>\$ 299</b>	<b>\$ 8,763</b>	<b>\$ 12,235</b>	<b>\$ (5,610)</b>	<b>\$ (6,727)</b>	<b>\$ 454</b>

Consolidated Changes in Equity for the Three Months Ended September 30, 2009	Total	Comprehensive Income	Preferred Stock	Common Stock	Additional Paid-in- Capital	Reinvested Earnings	Accumulated Other Comprehensive Loss	Treasury Stock	Noncontrolling Interests
Beginning balance	\$ 7,907		\$ 237	\$ 297	\$ 8,441	\$ 10,611	\$ (5,385)	\$ (6,727)	\$ 433
Comprehensive income:									
Net income	414	\$ 414				409			5
Other comprehensive income (loss), net of tax:									
Cumulative translation adjustment	55	55					55		
Net revaluation and clearance of cash flow hedges to earnings	22	22					22		
Pension benefit plans	50	50					50		
Other benefit plans	(9)	(9)					(9)		
Other comprehensive income	118	118							
Comprehensive income	532	\$ 532(1)							
Common dividends	(375)					(373)			(2)
Preferred dividends	(3)					(3)			

Edgar Filing: DUPONT E I DE NEMOURS & CO - Form 10-Q

Common stock issued - compensation plans	22			22						
Total Equity as of September 30, 2009	\$ 8,083	\$ 237	\$ 297	\$ 8,463	\$ 10,644	\$ (5,267)	\$ (6,727)	\$		436

(1) Includes comprehensive income attributable to noncontrolling interests of \$4 and \$5 for the three months ended September 30, 2010 and 2009, respectively.

Table of Contents

## NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

*(Dollars in millions, except per share)*

Consolidated Changes in Equity for the Nine Months Ended September 30, 2010	Total	Comprehensive Income	Preferred Stock	Common Stock	Additional Paid-in- Capital	Reinvested Earnings	Accumulated Other Comprehensive		Treasury Stock	Noncontrolling Interests
							Loss			
Beginning balance	\$ 7,651		\$ 237	\$ 297	\$ 8,469	\$ 10,710	\$ (5,771)	\$ (6,727)	\$	436
Comprehensive income:										
Net income	2,674	\$ 2,674				2,655				19
Other comprehensive income (loss), net of tax:										
Cumulative translation adjustment	(43)	(43)					(44)			1
Net revaluation and clearance of cash flow hedges to earnings	(11)	(11)					(11)			
Pension benefit plans	253	253					253			
Other benefit plans	(35)	(35)					(35)			
Net unrealized loss on securities	(2)	(2)					(2)			
Other comprehensive income	162	162								
Comprehensive income	2,836	\$ 2,836	(2)							
Common dividends	(1,124)					(1,122)				(2)
Preferred dividends	(8)					(8)				
Common stock issued - compensation plans	296			2	294					
<b>Total Equity as of September 30, 2010</b>	<b>\$ 9,651</b>		<b>\$ 237</b>	<b>\$ 299</b>	<b>\$ 8,763</b>	<b>\$ 12,235</b>	<b>\$ (5,610)</b>	<b>\$ (6,727)</b>	<b>\$</b>	<b>454</b>

Consolidated Changes in Equity for the Nine Months Ended September 30, 2009	Total	Comprehensive Income	Preferred Stock	Common Stock	Additional Paid-in- Capital	Reinvested Earnings	Accumulated Other Comprehensive		Treasury Stock	Noncontrolling Interests
							Loss			
Beginning balance	\$ 7,552		\$ 237	\$ 297	\$ 8,380	\$ 10,456	\$ (5,518)	\$ (6,727)	\$	427
Acquisition of a majority interest in a consolidated subsidiary										
	1									1
Purchase of subsidiary shares from noncontrolling interest										
	(1)									(1)
Comprehensive income:										
Net income	1,324	\$ 1,324				1,314				10
Other comprehensive income (loss), net of tax:										
Cumulative translation adjustment	80	80					80			
Net revaluation and clearance of cash flow hedges to earnings	62	62					60			2
Pension benefit plans	137	137					137			
Other benefit plans	(27)	(27)					(27)			
Net unrealized gain on securities	1	1					1			
Other comprehensive income	253	253								
Comprehensive income	1,577	\$ 1,577	(2)							
Common dividends	(1,121)					(1,118)				(3)
Preferred dividends	(8)					(8)				
Common stock issued - compensation plans	83				83					
<b>Total Equity as of September 30, 2009</b>	<b>\$ 8,083</b>		<b>\$ 237</b>	<b>\$ 297</b>	<b>\$ 8,463</b>	<b>\$ 10,644</b>	<b>\$ (5,267)</b>	<b>\$ (6,727)</b>	<b>\$</b>	<b>436</b>

---

(2) Includes comprehensive income attributable to noncontrolling interests of \$20 and \$12 for the nine months ended September 30, 2010 and 2009, respectively.

Table of Contents

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

*(Dollars in millions, except per share)*

**Note 11. Derivatives and Other Hedging Instruments**

*Objectives and Strategies for Holding Derivative Instruments*

In the ordinary course of business, the company enters into contractual arrangements (derivatives) to reduce its exposure to foreign currency, interest rate and commodity price risks under established procedures and controls. The company has established a variety of approved derivative instruments to be utilized in each financial risk management program, as well as varying levels of exposure coverage and time horizons based on an assessment of risk factors related to each hedging program. Derivative instruments utilized during the period include forwards, options, futures and swaps. The company has not designated any nonderivatives as hedging instruments.

The company established a financial risk management framework that incorporated the Corporate Financial Risk Management Committee and established financial risk management policies and guidelines that authorize the use of specific derivative instruments and further establishes procedures for control and valuation, counterparty credit approval and routine monitoring and reporting. The counterparties to these contractual arrangements are major financial institutions and major commodity exchanges. The company is exposed to credit loss in the event of nonperformance by these counterparties. The company manages this exposure to credit loss through the aforementioned credit approvals, limits and monitoring procedures and, to the extent possible, by restricting the period over which unpaid balances are allowed to accumulate. The company anticipates performance by counterparties to these contracts and therefore no material loss is expected. Market and counterparty credit risks associated with these instruments are regularly reported to management.

The company hedges foreign currency denominated revenue and monetary assets and liabilities, certain business specific foreign currency exposures and certain energy feedstock purchases. In addition, the company enters into agricultural commodity derivatives to hedge exposures relevant to agricultural feedstocks.

*Foreign Currency Risk*

The company's objective in managing exposure to foreign currency fluctuations is to reduce earnings and cash flow volatility associated with foreign currency rate changes. Accordingly, the company enters into various contracts that change in value as foreign exchange rates change to protect the value of its existing foreign currency-denominated assets, liabilities, commitments and cash flows.

The company routinely uses forward exchange contracts to offset its net exposures, by currency, related to the foreign currency-denominated monetary assets and liabilities of its operations. The primary business objective of this hedging program is to maintain an approximately balanced position in foreign currencies so that exchange gains and losses resulting from exchange rate changes, net of related tax effects, are minimized.



Interest Rate Risk

The company uses interest rate swaps to manage the interest rate mix of the total debt portfolio and related overall cost of borrowing.

Interest rate swaps involve the exchange of fixed for floating rate interest payments to effectively convert fixed rate debt into floating rate debt based on USD LIBOR. Interest rate swaps allow the company to achieve a target range of floating rate debt.

Commodity Price Risk

Commodity price risk management programs serve to reduce exposure to price fluctuations on purchases of inventory such as natural gas, copper, corn, soybeans and soybean meal.

The company enters into over-the-counter and exchange-traded derivative commodity instruments to hedge the commodity price risk associated with energy feedstock and agricultural commodity exposures.

Table of Contents

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

*(Dollars in millions, except per share)*

Fair Value Hedges

During the quarter ended September 30, 2010, the company maintained a number of interest rate swaps, implemented at the time the debt instruments were issued, that involve the exchange of fixed for floating rate interest payments. These swaps allow the company to achieve a target range of floating rate debt. All interest rate swaps qualify for the shortcut method of hedge accounting, thus there is no ineffectiveness related to these hedges. The company maintains no other significant fair value hedges. At September 30, 2010 and December 31, 2009, the company had interest rate swap agreements with gross notional amounts of approximately \$1,000 and \$1,900, respectively.

Cash Flow Hedges

The company maintains a number of cash flow hedging programs to reduce risks related to foreign currency and commodity price risk. While each risk management program has a different time maturity period, most programs currently do not extend beyond the next two-year period.

The company uses foreign currency exchange contracts to offset a portion of the company's exposure to certain foreign currency-denominated revenues so that gains and losses on these contracts offset changes in the U.S. dollar value of the related foreign currency-denominated revenues. At September 30, 2010 and December 31, 2009, the company had foreign currency exchange contracts with gross notional amounts of approximately \$1,348 and \$293, respectively.

A portion of natural gas purchases are hedged to reduce price volatility using fixed price swaps and options. At September 30, 2010 and December 31, 2009, the company had energy feedstock and other contracts with gross notional amounts of approximately \$182 and \$277, respectively.

The company contracts with independent growers to produce seed inventory. Under these contracts, growers are compensated with bushel equivalents that are sold to the company for the market price of grain for a period of time. Derivative instruments, such as commodity futures and options that have a high correlation to the underlying commodity, are used to hedge the commodity price risk involved in compensating growers.

The company utilizes agricultural commodity futures to manage the price volatility of soybean meal. These derivative instruments have a high correlation to the underlying commodity exposure and are deemed effective in offsetting soybean meal feedstock price risk.

## Edgar Filing: DUPONT E I DE NEMOURS & CO - Form 10-Q

At September 30, 2010 and December 31, 2009, the company had agricultural commodity contracts with gross notional amounts of approximately \$120 and \$332, respectively.

During the third quarter 2010, the company entered into treasury rate contracts to hedge the company's exposure to treasury rates on a portion of a planned bond issuance. The contracts were terminated in September 2010 at the time the bonds were issued.

Table of Contents**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS***(Dollars in millions, except per share)*

Cash flow hedge results are reclassified into earnings during the same period in which the related exposure impacts earnings. Reclassifications are made sooner if it appears that a forecasted transaction will not materialize. The following table summarizes the effect of cash flow hedges on accumulated other comprehensive income (loss) for the three and nine months ended September 30, 2010:

	Three Months Ended September 30, 2010			Nine Months Ended September 30, 2010		
	Pre-tax	Tax	After-Tax	Pre-tax	Tax	After-Tax
Beginning balance	\$ (119)	\$ 42	\$ (77)	\$ (101)	\$ 36	\$ (65)
Additions and revaluations of derivatives designated as cash flow hedges	(18)	6	(12)	(80)	29	(51)
Clearance of hedge results to earnings	20	(7)	13	64	(24)	40
Balance at September 30, 2010	\$ (117)	\$ 41	\$ (76)	\$ (117)	\$ 41	\$ (76)
Amounts expected to be reclassified into earnings over the next twelve months	\$ (101)	\$ 36	\$ (65)	\$ (101)	\$ 36	\$ (65)

Hedges of Net Investment in a Foreign Operation

During the quarter ended September 30, 2010, the company did not maintain any hedges of net investment in a foreign operation.

Derivatives not Designated in Hedging Relationships

The company uses forward exchange contracts to reduce its net exposure, by currency, related to foreign currency-denominated monetary assets and liabilities. The netting of such exposures precludes the use of hedge accounting. However, the required revaluation of the forward contracts and the associated foreign currency-denominated monetary assets and liabilities results in a minimal earnings impact, after taxes. At September 30, 2010 and December 31, 2009, the company had forward exchange contracts with gross notional amounts of approximately \$8,054 and \$7,634, respectively.

In addition, the company has risk management programs for agricultural commodities that do not qualify for hedge accounting treatment. At September 30, 2010 and December 31, 2009, the company had agricultural commodities contracts with gross notional amounts of approximately \$257 and \$206, respectively.

Contingent Features

During the quarter ended September 30, 2010, the company did not maintain any derivative contracts with credit-risk-related contingent features.

Table of Contents**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS***(Dollars in millions, except per share)*

The following tables provide information on the location and amounts of derivative fair values in the Condensed Consolidated Balance Sheet and derivative gains and losses in the Consolidated Income Statement:

Fair Values of Derivative Instruments

	Asset Derivatives		Liability Derivatives	
	September 30, 2010	December 31, 2009	September 30, 2010	December 31, 2009
<b>Derivatives designated as hedging instruments</b>				
Interest rate swaps	\$	\$	\$	\$
Interest rate swaps	67(2)	12(1)		12(4)
Foreign currency contracts	9(1)	3(1)	8(3)	
Energy feedstocks	2(1)	2(1)	78(3)	54(3)
Energy feedstocks			18(4)	49(4)
<b>Total derivatives designated as hedging instruments</b>	<b>\$ 78</b>	<b>\$ 17</b>	<b>\$ 104</b>	<b>\$ 115</b>
<b>Derivatives not designated as hedging instruments</b>				
Foreign currency contracts	18(1)	111(1)	219(3)	17(3)
<b>Total derivatives not designated as hedging instruments</b>	<b>\$ 18</b>	<b>\$ 111</b>	<b>\$ 219</b>	<b>\$ 17</b>
<b>Total derivatives</b>	<b>\$ 96</b>	<b>\$ 128</b>	<b>\$ 323</b>	<b>\$ 132</b>

- 
- (1) Current portion recorded in accounts and notes receivable, net.
- (2) Long-term portion recorded in other assets.
- (3) Current portion recorded in other accrued liabilities.
- (4) Long-term portion recorded in other liabilities.

The Effect of Derivative Instruments on the Consolidated Income Statement

*Fair Value Hedging*

Derivatives in Fair Value Hedging Relationships	Amount of Gain or (Loss) Recognized in Income of Derivative Three Months Ended September 30, 2010	Amount of Gain or (Loss) Recognized in Income on Hedged Item Three Months Ended September 30, 2010	Amount of Gain or (Loss) Recognized in Income of Derivative Three Months Ended September 30, 2009	Amount of Gain or (Loss) Recognized in Income on Hedged Item Three Months Ended September 30, 2009
Interest rate swaps	\$ 28(1)	\$ (28)(1)	\$ (7)(1)	\$ 7(1)
<b>Total</b>	<b>\$ 28</b>	<b>\$ (28)</b>	<b>\$ (7)</b>	<b>\$ 7</b>
	Nine Months Ended September 30, 2010	Nine Months Ended September 30, 2010	Nine Months Ended September 30, 2009	Nine Months Ended September 30, 2009
Interest rate swaps	\$ 67(1)	\$ (67)(1)	\$ (23)(1)	\$ 23(1)
<b>Total</b>	<b>\$ 67</b>	<b>\$ (67)</b>	<b>\$ (23)</b>	<b>\$ 23</b>

---

(1) Gain (loss) was recognized in interest expense, which offset to \$0.

Table of Contents

## NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

*(Dollars in millions, except per share)**Cash Flow Hedging*

		Amount of Gain or (Loss) Recognized in OCI(1) on Derivative (Effective Portion) Three Months Ended September 30, 2010	Amount of Gain or (Loss) Reclassified from Accumulated OCI(1) into Income (Effective Portion) Three Months Ended September 30, 2010	Amount of Gain or (Loss) Recognized in Income on Derivative (Ineffective Portion and Amount Excluded from Effectiveness Testing) Three Months Ended September 30, 2010
<b>Derivatives in Cash Flow Hedging Relationships</b>				
Treasury rate contracts	\$	(3)	\$	\$
Foreign currency contracts		(12)		(3)(2)
Agricultural feedstocks		11		2(3)
Energy feedstocks		(14)		(17)(3)
<b>Total</b>	<b>\$</b>	<b>(18)</b>	<b>\$</b>	<b>(20)</b>

		Nine Months Ended September 30, 2010		Nine Months Ended September 30, 2010		Nine Months Ended September 30, 2010
Treasury rate contracts	\$	(3)	\$		\$	
Foreign currency contracts		(2)		9	(2)	
Agricultural feedstocks		(31)		(21)	(3)	(1)(3)
Energy feedstocks		(44)		(52)	(3)	
<b>Total</b>	<b>\$</b>	<b>(80)</b>	<b>\$</b>	<b>(64)</b>		<b>(1)</b>

		Amount of Gain or (Loss) Recognized in OCI(1) on Derivative (Effective Portion) Three Months Ended September 30, 2009	Amount of Gain or (Loss) Reclassified from Accumulated OCI(1) into Income (Effective Portion) Three Months Ended September 30, 2009	Amount of Gain or (Loss) Recognized in Income on Derivative (Ineffective Portion and Amount Excluded from Effectiveness Testing) Three Months Ended September 30, 2009
<b>Derivatives in Cash Flow Hedging Relationships</b>				
Foreign currency contracts	\$	(7)	\$	(6)(2)
Agricultural feedstocks				2 (3)
Energy feedstocks		5		(32)(3)
<b>Total</b>	<b>\$</b>	<b>(2)</b>	<b>\$</b>	<b>(36)</b>

		Nine Months Ended September 30, 2009		Nine Months Ended September 30, 2009		Nine Months Ended September 30, 2009
Foreign currency contracts	\$	(9)	\$	(27)	(2)	\$
Agricultural feedstocks		(23)		(45)	(3)	(5)(3)
Energy feedstocks		(43)		(96)	(3)	
<b>Total</b>	<b>\$</b>	<b>(75)</b>	<b>\$</b>	<b>(168)</b>		<b>(5)</b>



Edgar Filing: DUPONT E I DE NEMOURS & CO - Form 10-Q

- (1) OCI is defined as other comprehensive income (loss).
- (2) Gain (loss) was reclassified from accumulated other comprehensive income into net sales.
- (3) Gain (loss) was recognized in cost of goods sold and other operating charges.

Table of Contents

## NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

*(Dollars in millions, except per share)**Derivatives not Designated in Hedging Instruments*

Derivatives Not Designated in Hedging Instruments	Amount of Gain or (Loss) Recognized in Income on Derivative		Amount of Gain or (Loss) Recognized in Income on Derivative	
	Three Months Ended September 30, 2010	Nine Months Ended September 30, 2010	Three Months Ended September 30, 2009	Nine Months Ended September 30, 2009
Foreign currency contracts	\$ (443)(1)	\$ 100(1)	\$ (318)(1)	\$ (490)(1)
Agricultural feedstocks	(20)(2)	5(2)	1 (2)	(3)(2)
<b>Total</b>	<b>\$ (463)</b>	<b>\$ 105</b>	<b>\$ (317)</b>	<b>\$ (493)</b>

(1) Gain (loss) recognized in other income, net, was partially offset by the related gain (loss) on the foreign currency denominated monetary assets and liabilities of the company's operations, which were \$283 and \$(125) for the three and nine months ended September 30, 2010, respectively, and \$190 and \$288 for the three and nine months ended September 30, 2009, respectively.

(2) Gain (loss) was recognized in cost of goods sold and other operating charges.

**Note 12. Long-Term Employee Benefits**

The following sets forth the components of the company's net periodic benefit cost for pensions:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2010	2009	2010	2009
Service cost	\$ 53	\$ 48	\$ 154	\$ 142
Interest cost	316	319	946	949
Expected return on plan assets	(360)	(403)	(1,076)	(1,200)
Amortization of unrecognized loss	126	70	379	209
Amortization of prior service cost	4	5	12	14
<b>Net periodic benefit cost</b>	<b>\$ 139</b>	<b>\$ 39</b>	<b>\$ 415</b>	<b>\$ 114</b>

The company made a voluntary contribution of \$500 to its principal U.S. pension plan in the third quarter 2010.

## Edgar Filing: DUPONT E I DE NEMOURS & CO - Form 10-Q

For the nine months ended September 30, 2010, the company contributed \$204 to its pension plans, other than the principal U.S. pension plan, and the company anticipates additional contributions during the remainder of 2010 to total approximately \$74.

Table of Contents**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS***(Dollars in millions, except per share)*

The following sets forth the components of the company's net periodic benefit cost for other long-term employee benefits:

	Three Months Ended September 30,				Nine Months Ended September 30,			
	2010		2009		2010		2009	
Service cost	\$	7	\$	7	\$	21	\$	23
Interest cost		60		62		179		184
Amortization of unrecognized loss		15		12		44		37
Amortization of prior service benefit		(27)		(26)		(80)		(79)
Net periodic benefit cost	\$	55	\$	55	\$	164	\$	165

For the nine months ended September 30, 2010, the company made benefit payments of \$232 related to its other long-term employee benefit plans and anticipates additional payments during the remainder of 2010 to total approximately \$109.

**Note 13. Segment Information**

Segment sales include transfers to another business segment. Products are transferred between segments on a basis intended to reflect, as nearly as practicable, the market value of the products. Segment pre-tax operating income (loss) (PTOI) is defined as operating income (loss) before income taxes, exchange gains (losses), corporate expenses and interest. Prior year data have been reclassified to reflect the current organizational structure.

Three Months Ended September 30,	Agriculture & Nutrition(2)	Electronics & Communications	Performance Chemicals	Performance Coatings	Performance Materials	Safety & Protection	Pharmaceuticals	Other	Total (1)
<b>2010</b>									
Segment sales	\$ 1,271	\$ 703	\$ 1,675	\$ 937	\$ 1,578	\$ 871	\$	\$ 49	\$ 7,084
Less transfers		(4)	(59)		(17)	(3)			(83)
Net sales	1,271	699	1,616	937	1,561	868		49	7,001
Pre-tax operating income (loss)	(181)	126	292	64	281	134	111	(64)	763
<b>2009</b>									
Segment sales	1,244	542	1,331	882	1,303	670		54	\$ 6,026
Less transfers		(6)	(43)		(13)	(3)			(65)
Net sales	1,244	536	1,288	882	1,290	667		54	5,961
Pre-tax operating income (loss)	(113)	77	207	58	230	58	266	(26)	757



Table of Contents

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

*(Dollars in millions, except per share)*

<b>Nine Months Ended September 30,</b>	<b>Agriculture &amp; Nutrition(2)</b>	<b>Electronics &amp; Communications</b>	<b>Performance Chemicals</b>	<b>Performance Coatings</b>	<b>Performance Materials</b>	<b>Safety &amp; Protection</b>	<b>Pharmaceuticals</b>	<b>Other</b>	<b>Total (1)</b>
<b>2010</b>									
Segment sales	\$ 7,543	\$ 1,991	\$ 4,658	\$ 2,801	\$ 4,688	\$ 2,505	\$	\$ 154	\$ 24,340
Less transfers	(1)	(13)	(162)	(1)	(54)	(8)			(239)
Net sales	7,542	1,978	4,496	2,800	4,634	2,497		154	24,101
Pre-tax operating income (loss)	1,522	339	756	184	772	357	402	(111)	4,221
<b>2009</b>									
Segment sales	6,919	1,336	3,644	2,454	3,332	2,052		113	\$ 19,850
Less transfers		(14)	(101)	(1)	(27)	(8)		(9)	(160)
Net sales	6,919	1,322	3,543	2,453	3,305	2,044		104	19,690
Pre-tax operating income (loss)			(3),	(3),	(3),	(3),		(3),	(3),
	1,319(3)	20(4)	330(4)	(9(4)	89(5)	116(4)	790	(113(4)	2,542

(1) A reconciliation of the pre-tax operating income totals reported for the operating segments to the applicable line item on the Consolidated Financial Statements is as follows:

	<b>Three Months Ended September 30,</b>		<b>Nine Months Ended September 30,</b>	
	<b>2010</b>	<b>2009</b>	<b>2010</b>	<b>2009</b>
Total segment PTOI	\$ 763	\$ 757	\$ 4,221	\$ 2,542
Net exchange gains (losses), including affiliates	(160)	(128)	(25)	(202)
Corporate expenses and net interest	(273)	(238)	(711)	(728)
Income before income taxes	\$ 330	\$ 391	\$ 3,485	\$ 1,612

(2) As of September 30, 2010, Agriculture & Nutrition net assets were \$8,797, an increase of \$2,585 from \$6,212 at December 31, 2009. The increase was primarily due to higher trade receivables due to normal seasonality in the sales and cash collections cycle.

(3) Includes a \$75 net reduction in estimated costs related to the 2008 restructuring program, in the following segments: Agriculture & Nutrition - \$(1); Performance Chemicals - \$3; Performance Coatings - \$42; Performance Materials - \$28; Safety & Protection - \$1; and Other - \$2. See Note 4 for additional information.

(4) Includes a \$(340) restructuring charge impacting the segments as follows: Electronics & Communications - \$(43); Performance Chemicals - \$(66); Performance Coatings - \$(65); Performance Materials - \$(110); Safety & Protection - \$(55); and Other - \$(1). See Note 4 for

additional information.

(5) Includes a \$50 benefit related to a reduction in the reserve for hurricane damage in 2008 for \$26, and initial insurance recoveries related to damage from Hurricane Ike in 2008 in the amount of \$24.

**Note 14. Subsequent Event**

In September 2010, the company issued \$500 of 1.95% Senior Notes due January 15, 2016, \$1,000 of 3.625% Senior Notes due January 15, 2021 and \$500 of 4.90% Senior Notes due January 15, 2041. The company elected to use the net proceeds of \$1,976 to redeem \$500 of its 5.00% Senior Notes due January 15, 2013 and \$830 of its 5.875% Senior Notes due January 15, 2014 and pay down \$500 in commercial paper issued to fund the voluntary contribution to its principal U.S. pension plan. The partial redemption of the outstanding 5.00% and 5.875% Senior Notes, which were classified as short-term borrowings as of September 30, 2010, settled on October 21, 2010 and will result in a pre-tax loss on the early extinguishment of debt of \$180 in the fourth quarter 2010.

Table of Contents

**Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

**Cautionary Statements About Forward-Looking Statements**

This report contains forward-looking statements which may be identified by their use of words like plans, expects, will, anticipates, intends, projects, estimates or other words of similar meaning. All statements that address expectations or projections about the future, including statements about the company's strategy for growth, product development, market position, expenditures and financial results, are forward-looking statements.

Forward-looking statements are based on certain assumptions and expectations of future events. The company cannot guarantee that these assumptions and expectations are accurate or will be realized. For some of the important factors that could cause the company's actual results to differ materially from those projected in any such forward-looking statements see the Risk Factors discussion set forth under Part II, Item 1A beginning on page 41. Additional risks and uncertainties not presently known to the company or that the company currently believes to be immaterial also could affect its businesses.

**Results of Operations**

Overview

Sales of \$7.0 billion for the third quarter increased 17 percent versus prior year, principally reflecting 14 percent higher volume, with increases across all geographic and most major product markets, supported by global economic growth, particularly in emerging markets(1). Net income attributable to DuPont for the third quarter was \$367 million versus \$409 million in 2009, the decline principally reflecting a decrease in income from Pharmaceuticals due to patent expirations. Programs for productivity and cost-cutting remain on track while focus continues on actions to support a strong balance sheet, cash generation, and capital productivity. The company continues to execute strategies for further development and growth of new products, particularly for agriculture, photovoltaics, and the alternative energy and materials industries.

Net Sales

Net sales for the third quarter 2010 were \$7.0 billion versus \$6.0 billion in the prior year, an increase of 17 percent, reflecting 14 percent higher sales volume, a 5 percent increase in local selling prices, a 1 percent negative impact from currency exchange rates and a 1 percent net reduction from portfolio changes. Sales volume was higher across all segments with volume increasing 13 percent in the United States and 14 percent outside the United States. Sales in emerging markets of \$2.7 billion improved 22 percent from 2009.

---

(1) Emerging markets include China, India and countries located in Latin America, Eastern and Central Europe, Middle East, Africa and Southeast Asia.





Edgar Filing: DUPONT E I DE NEMOURS & CO - Form 10-Q

Table of Contents

The table below shows a regional breakdown of net sales based on location of customers and percentage variances from the prior year:

	Three Months Ended September 30, 2010		Percent Change Due to:			
	2010 Net Sales (\$ Billions)	Percent Change vs. 2009	Local Price	Currency Effect	Volume	Portfolio
U.S.	\$ 2.2	17	5		13	(1)
Europe, Middle East & Africa (EMEA)	1.7	9	6	(8)	12	(1)
Asia Pacific	1.9	31	7	2	23	(1)
Latin America	1.1	11	4	1	9	(3)
Canada	0.1	21	3	2	17	(1)
Total Consolidated Sales	\$ 7.0	17	5	(1)	14	(1)

Net sales for the nine months ended September 30, 2010 were \$24.1 billion versus \$19.7 billion in the prior year, an increase of 22 percent. This increase reflects an 18 percent higher sales volume, a 4 percent increase in local selling prices, a 1 percent positive impact from currency exchange rates and a 1 percent net reduction from portfolio changes. Sales volume was higher across all segments with volume improving 13 percent in the United States and 22 percent outside the United States. Sales in emerging markets of \$7.4 billion improved 28 percent from 2009, and the percentage of total company sales in these markets increased to 31 percent from 29 percent.

	Nine Months Ended September 30, 2010		Percent Change Due to:			
	2010 Net Sales (\$ Billions)	Percent Change vs. 2009	Local Price	Currency Effect	Volume	Portfolio
U.S.	\$ 9.2	17	5		13	(1)
EMEA	6.2	16	3	(1)	14	
Asia Pacific	5.3	47	5	3	40	(1)
Latin America	2.6	16	3	3	12	(2)
Canada	0.8	24	4	11	10	(1)
Total Consolidated Sales	\$ 24.1	22	4	1	18	(1)

Other Income, Net

Third quarter 2010 other income, net, totaled \$66 million as compared to \$195 million in the prior year, a decrease of \$129 million. The decrease was attributable primarily to a \$155 million reduction of Cozaar®/Hyzaar® antihypertensive drugs income, which reflects the expiration of certain patents.

For the nine months ended September 30, 2010, other income, net, was \$890 million as compared to \$824 million last year, an increase of \$66 million. The increase was attributable primarily to a decrease in net pre-tax exchange losses of \$177 million combined with higher income from

equity affiliates of \$70 million, a benefit of \$59 million related to accrued interest associated with settlements of prior year

Table of Contents

income tax contingencies, an increase in net gains on sales of assets of \$53 million and an increase in insurance recoveries of \$38 million. The increase was partially offset by \$389 million reduction of Cozaar®/Hyzaar® income, which reflects the expiration of certain patents.

Additional information related to the company's other income, net, is included in Note 3 to the interim Consolidated Financial Statements.

Cost of Goods Sold and Other Operating Charges (COGS)

COGS totaled \$5.4 billion in the third quarter 2010 versus \$4.6 billion in the prior year, an increase of 19 percent. COGS as a percent of net sales was 78 percent versus 76 percent for the third quarter 2009. The 2 percentage point increase principally reflects higher raw material, energy and freight costs. Higher manufacturing utilization and selling prices substantially offset the impact of higher raw material, energy and freight costs.

COGS for the nine months ended September 30, 2010 was \$17.2 billion, an increase of 17 percent versus \$14.8 billion in the prior year. COGS was 71 percent of net sales, a 4 percentage point decrease from prior year. The improvement principally reflects increased manufacturing utilization from higher volume, higher selling prices and a small favorable impact from currency exchange rates. Raw material, energy and freight costs, adjusted for volume and currency, were up 4 percent. The company anticipates that full year 2010 raw material, energy and freight costs, adjusted for volume and currency, will increase 5 to 6 percent compared to prior year.

Selling, General and Administrative Expenses (SG&A)

SG&A totaled \$782 million for the third quarter 2010 versus \$770 million in the prior year. Year-to-date SG&A totaled \$2.8 billion versus \$2.6 billion in 2009. The increase for the three and nine months ended September 30, 2010 was due to higher selling expenses, primarily in the Agriculture & Nutrition segment as a result of increased global commissions and selling and marketing investments related to the company's seed products, and higher non-cash pension expenses. SG&A was approximately 11 percent and 12 percent of net sales for the three and nine month periods ended September 30, 2010, respectively, and 13 percent for the same periods in 2009.

Research and Development Expense (R&D)

R&D totaled \$409 million and \$335 million for the third quarter 2010 and 2009, respectively. For the nine month period ended September 30, 2010, R&D was \$1.2 billion versus \$1.0 billion last year. The increase for the three and nine months ended September 30, 2010 in R&D was due to continued growth investment in the Agriculture & Nutrition segment and higher non-cash pension expenses. R&D was approximately 6 percent of net sales for the three months ended September 30, 2010 and 2009 and 5 percent of net sales for the nine months ended September 30, 2010 and 2009.

Interest Expense

Interest expense totaled \$103 million in the third quarter 2010 compared to \$100 million in 2009. The increase in interest expense for the three months ended September 30, 2010 was due primarily to higher average debt. For the nine month period ended September 30, 2010, interest expense decreased from \$312 million in 2009 to \$309 million in 2010. The decrease in interest expense for the nine months ended September 30, 2010 was due primarily to lower rates partially offset by higher average debt.

Employee Separation / Asset Related Charges, Net

For the nine months ended September 30, 2009, the company recorded a \$340 million restructuring charge comprised of severance and related benefit costs, asset write-offs, and impairment charges, partially offset by a \$75 million net reduction in the estimated costs related to the 2008 restructuring program. The \$75 million net reduction in the estimated costs for the 2008 program was primarily due to work force reductions realized through non-severance programs and redeployments within the company.

Table of Contents

Additional information related to the company's restructuring programs is located in Note 4 to the interim Consolidated Financial Statements.

Provision for Income Taxes

The company's effective tax rate for the third quarter 2010 was (11.8) percent as compared to (5.9) percent in 2009. The lower effective tax rate in 2010 versus 2009 principally relates to the tax impact associated with the company's policy of hedging the foreign currency-denominated monetary assets and liabilities of its operations.

The company's effective tax rate for year-to-date 2010 was 23.3 percent as compared to 17.9 percent in 2009. The higher effective tax rate principally relates to the tax impact associated with the company's policy of hedging the foreign currency-denominated monetary assets and liabilities of its operations partially offset by favorable geographic mix of pre-tax earnings. See Note 5 to the interim Consolidated Financial Statements for additional information.

Net Income Attributable to DuPont (Earnings)

Earnings for the third quarter 2010 were \$367 million versus \$409 million in the third quarter 2009, down 10 percent. The earnings contribution from higher sales volume was more than offset by lower Pharmaceuticals income, higher non-cash pension costs and spending for growth initiatives. Higher local selling prices offset higher raw material, energy and freight costs adjusted for volume and currency.

For the nine months ended September 30, 2010, earnings were \$2.7 billion, compared to \$1.3 billion in the prior year. The increase principally reflects higher sales volume and selling prices, the absence of a prior year restructuring charge and a favorable currency impact, partly offset by higher non-cash pension costs and lower Pharmaceuticals income.

Corporate Outlook

The company expects full-year 2010 earnings of about \$3.06 per share. This outlook includes an expected \$0.13 per share charge in the fourth quarter associated with the company's early extinguishment of debt, partly offset by a \$0.09 per share benefit in the second quarter associated with an adjustment of interest and accruals related to prior year income tax settlements. The outlook also assumes Pharmaceuticals full year pre-tax income will be about \$480 million. The company expects full year free cash flow to be about \$1.7 billion.

Health Care Reform

## Edgar Filing: DUPONT E I DE NEMOURS & CO - Form 10-Q

During March 2010, a comprehensive health care reform legislation was signed into law in the U.S. under the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (the Acts). Included among the major provisions of the law is a change in tax treatment of the federal drug subsidy paid with respect to Medicare-eligible retirees. This change did not have a significant impact because the company operates its principal drug plan for Medicare-eligible retirees as secondary to Medicare and manages Medicare Part D reimbursement through a third party administrator. The effect of the Acts on the company's other long-term employee benefit obligation and cost depends on finalization of related regulatory requirements. The company will continue to monitor and assess the effect of the Acts as the regulatory requirements are finalized.

### Segment Reviews

Summarized below are comments on individual segment sales and pre-tax operating income (loss) (PTOI) for the three and nine month periods ended September 30, 2010 compared with the same periods in 2009. Segment sales include transfers to another business segment. Products are transferred between segments on a basis intended to reflect, as nearly as practicable, the market value of the products. Segment PTOI is defined as operating income before income taxes, exchange gains (losses), corporate expenses and interest. All references to selling prices are on a U.S. dollar (USD) basis, including the impact of currency. A reconciliation of segment sales to consolidated net sales and segment PTOI to income

Table of Contents

before income taxes for the three and nine month periods ended September 30, 2010 and 2009 is included in Note 13 to the interim Consolidated Financial Statements.

The following tables summarize third quarter and year-to-date 2010 segment sales and related variances versus prior year:

	Three Months Ended September 30, 2010		Percentage Change Due to:		
	Segment Sales* (\$ Billions)	Percent Change vs. 2009	Selling Price	Volume	Portfolio and Other
Agriculture & Nutrition	\$ 1.3	2		5	(3)
Electronics & Communications	0.7	30	6	24	
Performance Chemicals	1.7	26	12	15	(1)
Performance Coatings	0.9	6	1	5	
Performance Materials	1.6	21	4	19	(2)
Safety & Protection	0.9	30	(1)	31	

\* Segment sales include transfers

	Nine Months Ended September 30, 2010		Percentage Change Due to:		
	Segment Sales* (\$ Billions)	Percent Change vs. 2009	Selling Price	Volume	Portfolio and Other
Agriculture & Nutrition	\$ 7.5	9	4	6	(1)
Electronics & Communications	2.0	49	6	43	
Performance Chemicals	4.7	28	8	21	(1)
Performance Coatings	2.8	14	3	11	
Performance Materials	4.7	41	7	35	(1)
Safety & Protection	2.5	22		22	

\* Segment sales include transfers

**Agriculture & Nutrition** Third quarter 2010 sales of \$1.3 billion increased 2 percent, principally reflecting 5 percent higher volume, partially offset by crop protection portfolio changes of 3 percent. Increased sales primarily reflect technology penetration in the Latin American seed market and broad-based sales increase of Rynaxypyr® insecticide. Segment PTOI for the third quarter was a loss of \$181 million, compared to a loss of \$113 million in the third quarter 2009, reflecting growth investments and the impact of divested businesses.

Year-to-date sales were \$7.5 billion, a 9 percent increase versus the prior year, reflecting a 6 percent increase in volume and 4 percent higher selling prices. Higher volume was primarily due to higher seed sales in North America coupled with higher global sales of crop protection products, led by strong demand for Rynaxypyr®. Year-to-date PTOI was \$1.5 billion, up 15 percent versus \$1.3 billion in the same period last year, principally due to higher sales, partially offset by anticipated growth investments.



**Electronics & Communications** Third quarter 2010 sales of \$703 million increased \$161 million, or 30 percent, reflecting 24 percent higher volume and 6 percent higher selling prices, primarily pass-through of metals prices. Higher volume was primarily due to growth in all regions, particularly in Asia Pacific and Europe, and strong demand across most market segments, particularly in photovoltaics. PTOI of \$126 million was up \$49 million reflecting significantly higher volume.

Table of Contents

Year-to-date sales of \$2.0 billion were up 49 percent, with 43 percent higher volume and 6 percent higher selling prices. The higher volume reflects strong global demand across all regions, primarily in Asia Pacific and Europe. Year-to-date PTOI was \$339 million, an improvement of \$319 million from the same period last year. The increase in PTOI was driven by substantially higher volume and the absence of a \$43 million restructuring charge in the prior year.

**Performance Chemicals** Third quarter 2010 sales of \$1.7 billion increased \$0.3 billion, or 26 percent, primarily due to a 15 percent increase in volume and 12 percent higher selling prices. The sales increase occurred in all regions, primarily in North America and Asia Pacific, and was driven by strong demand across most market segments, particularly for titanium dioxide, fluoropolymers and industrial chemicals. PTOI was \$292 million, an improvement of \$85 million, primarily due to higher volume and selling prices.

Year-to-date sales of \$4.7 billion increased 28 percent from the same period last year, reflecting 21 percent higher volume and 8 percent higher selling prices. The sales increase was primarily driven by continued broad-based recovery in all markets and regions, reflecting strong demand for titanium dioxide, fluoropolymers and refrigerants. Year-to-date PTOI was \$756 million, an improvement of \$426 million. The increase in PTOI was driven by higher volume and the absence of a net \$63 million restructuring charge in the prior year.

**Performance Coatings** Third quarter 2010 sales of \$937 million increased \$55 million, primarily reflecting 5 percent higher volume. Higher volume reflects continued strengthening in North American and European heavy duty truck markets, and increased demand in global automotive markets, most significant in North America. PTOI was \$64 million, up 10 percent from higher volume.

Year-to-date sales of \$2.8 billion increased 14 percent from the same period last year, reflecting 11 percent higher volume and a 3 percent increase in selling prices. Higher volume reflects continued recovery in global automotive OEM markets as a result of higher global motor vehicle builds, and strong demand across most regions. Year-to-date PTOI was \$184 million, an improvement of \$193 million from the same period last year. The increase in PTOI primarily reflects the impact of higher volume and the absence of a net \$23 million restructuring charge recorded in the prior year.

**Performance Materials** Third quarter 2010 sales of \$1.6 billion increased \$0.3 billion, or 21 percent, with 19 percent higher volume and a 4 percent increase in selling prices. The higher volume reflects strong demand in automotive, electronic and packaging markets, with growth in all regions, particularly Asia Pacific. PTOI was \$281 million, an improvement of 22 percent from higher volume and selling prices, partially offset by the absence of a \$24 million benefit from insurance recoveries in the prior year.

Year-to-date sales were \$4.7 billion versus \$3.3 billion in the same period last year. The 41 percent increase in sales is due to 35 percent higher volume and a 7 percent increase in selling prices. The higher volume was led by continued improvement in most markets, with strong volume recovery in all regions, led by Asia Pacific. Year-to-date PTOI was \$772 million, an improvement of \$683 million from the same period last year. The increase in PTOI was primarily driven by higher sales

**Safety & Protection** Third quarter 2010 sales of \$871 million increased \$201 million, or 30 percent, primarily due to higher volume. Growth primarily reflects increased demand for aramid and nonwoven products due to strengthening in industrial markets, and strong demand across all regions. PTOI was \$134 million, an improvement of \$76 million from higher volume and the absence of a \$26 million asset impairment charge

in the prior year.

Year-to-date sales of \$2.5 billion were 22 percent higher than prior year, principally due to higher volume. The increase in volume reflects increased demand across all markets and regions as strong recovery continued to occur. Year-to-date PTOI was \$357 million compared to \$116 million in the same period last year. The increase in earnings was primarily due to higher volume and the absence of a net \$54 million restructuring charge in prior year.

Table of Contents

**Pharmaceuticals** Third quarter PTOI was \$111 million compared to \$266 million in the third quarter 2009. Year-to-date 2010 PTOI was \$402 million compared to \$790 million in the prior year. The decreased income reflects the expiration of certain patents for Cozaar®/Hyzaar®.

**Other** The company includes embryonic businesses not included in growth platforms, such as Applied BioSciences and nonaligned businesses in Other. Sales in the third quarter of \$49 million decreased 9 percent from the third quarter 2009 due to lower sales from the Applied BioSciences business. PTOI for the third quarter 2010 was a loss of \$64 million, compared to a loss of \$26 million in the third quarter 2009. The increase in losses reflects lower sales and charges related to discontinued businesses.

Year-to-date sales were \$154 million compared to \$113 million in 2009. Year-to-date pre-tax operating loss was \$111 million, compared to pre-tax operating loss of \$113 million in the same period last year.

**Liquidity & Capital Resources**

Management believes the company's ability to generate cash from operations and access to capital markets will be adequate to meet anticipated cash requirements to fund working capital, capital spending, dividend payments, debt maturities and other cash needs. The company's liquidity needs can be met through a variety of sources, including: cash provided by operating activities, cash and cash equivalents, marketable securities, commercial paper, syndicated credit lines, bilateral credit lines, equity and long-term debt markets and asset sales. The company's current strong financial position, liquidity and credit ratings provide excellent access to the capital markets. In addition, cash generating actions have been implemented including spending reductions and restructuring to better align capital expenditures and costs. The company will continue to monitor the financial markets in order to respond to changing conditions.

Pursuant to its cash discipline policy, the company seeks first to maintain a strong balance sheet and second, to return excess cash to shareholders unless the opportunity to invest for growth is compelling. Cash and cash equivalents and marketable securities balances of \$6.0 billion as of September 30, 2010, provide primary liquidity to support all short-term obligations. The company has access to approximately \$2.5 billion in unused credit lines with several major financial institutions, as additional support to meet short term liquidity needs.

The company continually reviews its debt portfolio and occasionally may rebalance it to ensure adequate liquidity and an optimum debt maturity schedule. In September 2010, the company issued \$2.0 billion of five, ten and thirty year notes in the amount of \$0.5 billion, \$1.0 billion and \$0.5 billion, respectively. The company elected to use the net proceeds to redeem \$0.5 billion of its 5.00% Senior Notes due January 15, 2013 and \$0.8 billion of its 5.875% Senior Notes due January 15, 2014 and pay down commercial paper issued to fund the \$0.5 billion voluntary contribution to its principal U.S. pension plan.

During the first quarter 2010, Standard & Poor's revised the company's credit outlook to Stable from Negative and Fitch Ratings affirmed the company's current credit rating. With the company's \$2.0 billion bond issuance in September 2010, Standard & Poor's, Moody's Investors Service and Fitch Ratings all affirmed their current ratings.

## Edgar Filing: DUPONT E I DE NEMOURS & CO - Form 10-Q

The company's credit ratings impact its access to the debt capital market and cost of capital. The company's long term and short term credit ratings are as follows:

	<b>Long term</b>	<b>Short term</b>	<b>Outlook</b>
Standard & Poor's	A	A-1	Stable
Moody's Investors Service	A2	P-1	Negative
Fitch Ratings	A	F1	Negative

Cash provided by operating activities was \$35 million for the nine months ended September 30, 2010 compared to \$923 million during the same period ended in 2009. The \$888 million reduction is primarily due to an increase in the change in working capital, mainly driven by higher changes in inventory and

Table of Contents

accounts receivable due to higher sales, the stronger dollar, which was hedged with forward exchange contracts reflected in investing activities, and a voluntary contribution to the principal U.S. pension plan, partially offset by higher earnings.

Cash used for investing activities was \$0.3 billion for the nine months ended September 30, 2010 compared to \$2.6 billion for the same period last year. The \$2.3 billion change was mainly due to a reduction in investments in short-term financial instruments and a net increase in proceeds from forward exchange contract settlements. Purchases of property, plant and equipment for the nine months ended September 30, 2010 totaled \$899 million, a decrease of \$91 million compared to the prior year.

Cash provided by financing activities was \$386 million for the nine months ended September 30, 2010 compared to \$275 million for the same period last year. The \$111 million increase was primarily due to an increase in proceeds from the exercise of stock options.

(Dollars in millions)	Nine Months Ended September 30,	
	2010	2009
Cash provided by operating activities	\$ 35	\$ 923
Purchases of property, plant and equipment	(899)	(990)
<b>Free cash flow</b>	<b>\$ (864)</b>	<b>\$ (67)</b>

Free cash flow for the nine months ended September 30, 2010 was an outflow of \$864 million, as compared to an outflow of \$67 million for the same period last year. The company expects full year free cash flow to be about \$1.7 billion, reflecting the seasonal fourth quarter inflow from working capital decreases, while continuing to support growth investments including \$1.4 billion of capital investment.

Free cash flow is a measurement not recognized in accordance with generally accepted accounting principles (GAAP) and should not be viewed as an alternative to GAAP measures of performance. All companies do not calculate non-GAAP financial measures in the same manner and, accordingly, the company's free cash flow definition may not be consistent with the methodologies used by other companies. The company defines free cash flow as cash provided by operating activities less purchases of property, plant and equipment, and therefore indicates operating cash flow available for payment of dividends, other investing activities, and other financing activities. Free cash flow is useful to investors and management to evaluate the company's cash flow and financial performance, and is an integral financial measure used in the company's financial planning process.

Dividends paid to shareholders during the nine months ended September 30, 2010 totaled \$1.1 billion, including the third quarter 2010 dividend declared on July 22, 2010. In October 2010, the company's Board of Directors declared a fourth quarter common stock dividend of \$0.41 per share. The fourth quarter dividend was the company's 425th consecutive quarterly dividend since the company's first dividend in the fourth quarter 1904.

Cash and Cash Equivalents and Marketable Securities

## Edgar Filing: DUPONT E I DE NEMOURS & CO - Form 10-Q

Cash and cash equivalents and marketable securities were \$6.0 billion at September 30, 2010, a decrease of \$0.1 billion from \$6.1 billion at December 31, 2009.

### Debt

Total debt at September 30, 2010 was \$12.4 billion, an increase of \$1.4 billion from \$11.0 billion at December 31, 2009. The increase was primarily due to the issuance in the third quarter 2010 of \$0.5 billion of 1.95% Senior Notes due January 15, 2016, \$1.0 billion of 3.625% Senior Notes due January 15, 2021 and \$0.5 billion of 4.90% Senior Notes due January 15, 2041. The increase was partially offset by the use of cash to pay down debt of \$0.9 billion in the second quarter.

Table of Contents

Guarantees and Off-Balance Sheet Arrangements

For detailed information related to Guarantees, Indemnifications, Obligations for Equity Affiliates and Others and Certain Derivative Instruments, see pages 37 - 38 of the company's 2009 Annual Report, and Note 9 to the interim Consolidated Financial Statements.

**Contractual Obligations**

Information related to the company's contractual obligations at December 31, 2009 can be found on page 39 of the company's 2009 Annual Report. The company's contractual obligations at September 30, 2010 have increased approximately \$3.0 billion versus prior year-end. The increase is primarily attributable to the net increase in debt and an increase in the purchase obligations related to supply agreements entered into with INVISTA. In September 2010, the company entered into four raw material supply agreements with INVISTA beginning January 2013, with terms from 5 to 10 years. The total purchase obligation of these agreements at September 30, 2010 was \$1.3 billion.

**PFOA**

The following is an update of the PFOA discussion found on pages 45-47 of the company's 2009 Annual Report.

DuPont respects EPA's position raising questions about exposure routes and the potential toxicity of PFOA and DuPont and other companies have outlined plans to continue research, emission reduction and product stewardship activities to help address EPA's questions. In January 2006, DuPont pledged its commitment to EPA's 2010/15 PFOA Stewardship Program. The EPA program asks participants (1) to commit to achieve, no later than 2010, a 95 percent reduction in both facility emissions and product content levels of PFOA, PFOA precursors and related higher homologue chemicals and (2) to commit to working toward the elimination of PFOA, PFOA precursors and related higher homologue chemicals from emissions and products by no later than 2015. In October 2009, (for the year 2008), DuPont reported to EPA that it had achieved about a 99 percent reduction of PFOA emissions in U.S. manufacturing facilities. The company achieved about a 98 percent reduction in global manufacturing emissions, exceeding EPA's 2010 objective. In February 2007, DuPont announced its commitment to no longer make, use or buy PFOA by 2015, or sooner if possible. DuPont has developed PFOA replacement technology and successfully used this technology in its global manufacturing facilities to produce test materials for all major fluoropolymer product lines. DuPont has begun to supply fluoropolymer products without PFOA to customers for testing in their processes, and is working to obtain appropriate regulatory approvals for this technology. 3M filed suit against the company in March 2010, alleging that certain DuPont fluoropolymer dispersion products infringe its patents. In September 2010, the companies agreed to settle the suit through patent cross licenses.

DuPont has established reserves in connection with certain PFOA environmental and litigation matters (see Note 9 to the interim Consolidated Financial Statements).



Table of Contents

**Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

See Note 11, *Derivatives and Other Hedging Instruments* to the interim Consolidated Financial Statements. See also Part II, Item 7A, *Quantitative and Qualitative Disclosures About Market Risk*, on pages 48 - 50 of the company's 2009 Annual Report for information on the company's utilization of financial instruments and an analysis of the sensitivity of these instruments.

Table of Contents

**Item 4. CONTROLS AND PROCEDURES**

a) Evaluation of Disclosure Controls and Procedures

The company maintains a system of disclosure controls and procedures to give reasonable assurance that information required to be disclosed in the company's reports filed or submitted under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission. These controls and procedures also give reasonable assurance that information required to be disclosed in such reports is accumulated and communicated to management to allow timely decisions regarding required disclosures.

As of September 30, 2010, the company's Chief Executive Officer (CEO) and Chief Financial Officer (CFO), together with management, conducted an evaluation of the effectiveness of the company's disclosure controls and procedures pursuant to Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Based on that evaluation, the CEO and CFO concluded that these disclosure controls and procedures are effective.

b) Changes in Internal Control over Financial Reporting

There has been no change in the company's internal control over financial reporting that occurred during the quarter ended September 30, 2010 that has materially affected or is reasonably likely to materially affect the company's internal control over financial reporting.

Table of Contents

**PART II. OTHER INFORMATION**

**Item 1. LEGAL PROCEEDINGS**

The company is subject to various litigation matters, including, but not limited to, product liability, patent infringement, antitrust claims, and claims for third party property damage or personal injury stemming from alleged environmental torts. Information regarding certain of these matters is set forth below and in Note 9 to the interim Consolidated Financial Statements.

**Litigation**

*PFOA: Environmental and Litigation Proceedings*

For purposes of this report, the term PFOA means collectively perfluorooctanoic acid and its salts, including the ammonium salt and does not distinguish between the two forms. Information related to this matter is included in Note 9 to the interim Consolidated Financial Statements under the heading PFOA.

**Environmental Proceedings**

*Belle Plant, West Virginia*

The U.S. Environmental Protection Agency (EPA) is investigating three chemical releases at DuPont's Belle facility in West Virginia which occurred in January 2010. One of the releases involved the death of a DuPont employee after exposure to phosgene.

*Chambers Works Plant, Deepwater, New Jersey*

In September 2009, the New Jersey Department of Environmental Protection (NJDEP) notified DuPont that it was seeking administrative penalties for past violations of the New Jersey Air Regulations governing Leak Detection and Reporting (LDAR) at the Chambers Works facility. These violations were self-reported by the company in March 2009. NJDEP sought \$444,000.00 in administrative penalties for alleged violations during calendar year 2006. In fourth quarter 2009, DuPont filed an appeal regarding the basis of the penalty assessment and began settlement negotiations with NJDEP. The parties have agreed to settle the matter for \$87,000.00.

Edgar Filing: DUPONT E I DE NEMOURS & CO - Form 10-Q

Chambers Works Plant, Deepwater, New Jersey

In January 2010, EPA and the U.S. Attorney's Office for New Jersey, informed DuPont that the government was initiating an enforcement action arising from alleged environmental non-compliance at the Chambers Works facility. The government alleges that the facility violated recordkeeping requirements of certain provisions of the Clean Air Act and the Federal Clean Air Act Regulations governing LDAR and that it failed to report fugitive emissions of a compound from Chambers Works' waste water treatment facility under the Emergency Planning and Community Right-to-Know Act (EPCRA.) The alleged non-compliance was identified by EPA in 2007 and 2009 following separate environmental audits. DuPont is in settlement negotiations with EPA and the Department of Justice (DOJ).

Chambers Works Plant, Deepwater, New Jersey

On September 29, 2010, DuPont received a draft Administrative Consent Order (ACO) from the NJDEP seeking a penalty for alleged violations of New Jersey hazardous waste regulations dating back to April 2009 based on a facility-wide hazardous waste audit conducted in May 2010. DuPont is in negotiations with NJDEP.

Table of Contents

Chambers Works Plant, Deepwater, New Jersey

DuPont is in settlement negotiations with EPA and DOJ concerning allegations of environmental non-compliance at the Chambers Works facility. The allegations arose from an ongoing investigation into DuPont's management of hazardous waste in rail cars.

TSCA Voluntary Audit

DuPont voluntarily undertook a self-audit concerning reporting of inhalation studies pursuant to Toxic Substances Control Act (TSCA) section 8(e). DuPont voluntarily reported the results of that audit to EPA. EPA has reviewed the information submitted under this self-audit and has indicated potential violations exist with respect to some of the submitted studies. EPA and the company have reached an agreement in principle to settle this matter for a penalty of \$3.3 million.

**Item 1A. RISK FACTORS**

The company's operations could be affected by various risks, many of which are beyond its control. Based on current information, the company believes that the following identifies the most significant risk factors that could affect its businesses. Past financial performance may not be a reliable indicator of future performance and historical trends should not be used to anticipate results or trends in future periods.

**Price increases for energy and raw materials could have a significant impact on the company's ability to sustain and grow earnings.**

The company's manufacturing processes consume significant amounts of energy and raw materials, the costs of which are subject to worldwide supply and demand as well as other factors beyond the control of the company. Significant variations in the cost of energy, which primarily reflect market prices for oil and natural gas and raw materials affect the company's operating results from period to period. Legislation to address climate change by reducing greenhouse gas emissions and establishing a price on carbon could create increases in energy costs and price volatility. When possible, the company purchases raw materials through negotiated long-term contracts to minimize the impact of price fluctuations. Additionally, the company enters into over-the-counter and exchange traded derivative commodity instruments to hedge its exposure to price fluctuations on certain raw material purchases. The company takes actions to offset the effects of higher energy and raw material costs through selling price increases, productivity improvements and cost reduction programs. Success in offsetting higher raw material costs with price increases is largely influenced by competitive and economic conditions and could vary significantly depending on the market served. If the company is not able to fully offset the effects of higher energy and raw material costs, it could have a significant impact on the company's financial results.

**Failure to develop and market new products could impact the company's competitive position and have an adverse effect on the company's financial results.**

## Edgar Filing: DUPONT E I DE NEMOURS & CO - Form 10-Q

The company's operating results are largely dependent on its ability to renew its pipeline of new products and services and to bring those products and services to market. The company plans to grow earnings by focusing on emerging markets and solutions to meet increasing demand for food productivity, decrease dependency on fossil fuels and protect people, assets and the environment. This ability could be adversely affected by difficulties or delays in product development such as the inability to identify viable new products, successfully complete research and development, obtain relevant regulatory approvals, obtain intellectual property protection, or gain market acceptance of new products and services. Because of the lengthy development process, technological challenges and intense competition, there can be no assurance that any of the products the company is currently developing, or could begin to develop in the future, will achieve substantial commercial success. Sales of the company's new products could replace sales of some of its current products, offsetting the benefit of even a successful product introduction.

Table of Contents

**The company's results of operations could be adversely affected by litigation and other commitments and contingencies.**

The company faces risks arising from various unasserted and asserted litigation matters, including, but not limited to, product liability, patent infringement, antitrust claims, and claims for third party property damage or personal injury stemming from alleged environmental torts. The company has noted a nationwide trend in purported class actions against chemical manufacturers generally seeking relief such as medical monitoring, property damages, off-site remediation and punitive damages arising from alleged environmental torts without claiming present personal injuries. The company also has noted a trend in public and private nuisance suits being filed on behalf of states, counties, cities and utilities alleging harm to the general public. Various factors or developments can lead to changes in current estimates of liabilities such as a final adverse judgment, significant settlement or changes in applicable law. A future adverse ruling or unfavorable development could result in future charges that could have a material adverse effect on the company. An adverse outcome in any one or more of these matters could be material to the company's financial results.

In the ordinary course of business, the company may make certain commitments, including representations, warranties and indemnities relating to current and past operations, including those related to divested businesses and issue guarantees of third party obligations. If the company were required to make payments as a result, they could exceed the amounts accrued, thereby adversely affecting the company's results of operations.

Failure to appropriately manage safety, human health, product liability and environmental risks associated with the company's products and production processes could adversely impact employees, communities, stakeholders and results of operations. While the company has procedures and controls to manage such risks, process safety issues could be created by events outside of its control including natural disasters, severe weather events and acts of sabotage.

**As a result of the company's current and past operations, including operations related to divested businesses, the company could incur significant environmental liabilities.**

The company is subject to various laws and regulations around the world governing the environment, including the discharge of pollutants and the management and disposal of hazardous substances. As a result of its operations, including its past operations and operations of divested businesses, the company could incur substantial costs, including cleanup costs. The costs of complying with complex environmental laws and regulations, as well as internal voluntary programs, are significant and will continue to be so for the foreseeable future. The ultimate costs under environmental laws and the timing of these costs are difficult to predict. The company's accruals for such costs and liabilities may not be adequate because the estimates on which the accruals are based depend on a number of factors including the nature of the matter, the complexity of the site, site geology, the nature and extent of contamination, the type of remedy, the outcome of discussions with regulatory agencies and other Potentially Responsible Parties (PRPs) at multi-party sites and the number and financial viability of other PRPs.

**The company's ability to generate sales from genetically modified products, particularly seeds and other agricultural products, could be adversely affected by market acceptance, government policies, rules or regulations and competition.**

The company is using biotechnology to create and improve products, particularly in its Agriculture & Nutrition segment. The use of biotechnology to characterize the genetic and performance characteristics of Pioneer seeds provides Pioneer with competitive advantages in the development of new products, and in the most effective placement of those products on customer acres. Demand for these products could be

affected by market acceptance of genetically modified products as well as governmental policies, laws and regulations that affect the development, manufacture and distribution of products, including the testing and planting of seeds containing biotechnology traits and the import of commodity grain grown from those seeds.



Table of Contents

The company competes with major global companies that have strong intellectual property estates supporting the use of biotechnology to enhance products, particularly in the agricultural products and production markets. Speed in discovering and protecting new technologies and bringing products based on them to market is a significant competitive advantage. Failure to predict and respond effectively to this competition could cause the company's existing or candidate products to become less competitive, adversely affecting sales.

**Changes in government policies and laws could adversely affect the company's financial results.**

Sales outside the U.S. constitute approximately 60 percent of the company's 2009 revenue. The company anticipates that international sales will continue to represent a substantial portion of its total sales and that continued growth and profitability will require further international expansion, particularly in emerging markets. Sales from emerging markets represent approximately 30 percent of the company's revenue in 2009 and the company's growth plans include focusing on expanding its presence in emerging markets. The company's financial results could be affected by changes in trade, monetary and fiscal policies, laws and regulations, or other activities of U.S. and non-U.S. governments, agencies and similar organizations. These conditions include, but are not limited to, changes in a country's or region's economic or political conditions, trade regulations affecting production, pricing and marketing of products, local labor conditions and regulations, reduced protection of intellectual property rights in some countries, changes in the regulatory or legal environment, restrictions on currency exchange activities, burdensome taxes and tariffs and other trade barriers. International risks and uncertainties, including changing social and economic conditions as well as terrorism, political hostilities and war, could lead to reduced sales and profitability.

**Economic factors, including inflation, deflation and fluctuations in currency exchange rates, interest rates and commodity prices could affect the company's financial results.**

The company is exposed to fluctuations in currency exchange rates, interest rates and commodity prices. Because the company has significant international operations, there are a large number of currency transactions that result from international sales, purchases, investments and borrowings. The company actively manages currency exposures that are associated with monetary asset positions, committed currency purchases and sales, foreign currency-denominated revenues and other assets and liabilities created in the normal course of business. Failure to successfully manage these risks could have an adverse impact on the company's financial position, results of operations and cash flows.

**Conditions in the global economy and global capital markets may adversely affect the company's results of operations, financial condition, and cash flows.**

The company's business and operating results may in the future be adversely affected by global economic conditions, including instability in credit markets, declining consumer and business confidence, fluctuating commodity prices, volatile exchange rates, and other challenges that could affect the global economy. The company's customers may experience deterioration of their businesses, cash flow shortages, and difficulty obtaining financing. As a result, existing or potential customers may delay or cancel plans to purchase products and may not be able to fulfill their obligations in a timely fashion. Further, suppliers could experience similar conditions, which could impact their ability to fulfill their obligations to the company. Adversity within capital markets may impact future return on pension assets, thus resulting in greater future pension costs that impact the company's results. Future weakness in the global economy could adversely affect the company's results of operations, financial condition and cash flows in future periods.

**Business disruptions could seriously impact the company's future revenue and financial condition and increase costs and expenses.**

Business disruptions, including supply disruptions, increasing costs for energy, temporary plant and/or power outages and information technology system and network disruptions, could seriously harm the company's operations as well as the operations of its customers and suppliers. Although it is impossible to predict the occurrences or consequences of any such events, they could result in reduced demand for the company's products, make it difficult or impossible for the company to deliver products to its customers or to receive raw materials from suppliers, and create delays and inefficiencies in the supply

Table of Contents

chain. The company actively manages the risks within its control that could cause business disruptions to mitigate any potential impact from business disruptions regardless of cause including acts of terrorism or war, and natural disasters. Despite these efforts, the impact from business disruptions could significantly increase the cost of doing business or otherwise adversely impact the company's financial performance.

**Inability to protect and enforce the company's intellectual property rights could adversely affect the company's financial results.**

Intellectual property rights are important to the company's business. The company endeavors to protect its intellectual property rights in jurisdictions in which its products are produced or used and in jurisdictions into which its products are imported. However, the company may be unable to obtain protection for its intellectual property in key jurisdictions. Additionally, the company has designed and implemented internal controls to restrict access to and distribution of its intellectual property, including confidential information and trade secrets. Despite these precautions, it is possible that unauthorized parties may access and use such property. When misappropriation is discovered, the company reports such situations to the appropriate governmental authorities for investigation and takes measures to mitigate any potential impact.

**Item 6. EXHIBITS**

Exhibits: The list of exhibits in the Exhibit Index to this report is incorporated herein by reference.

Table of Contents

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

E. I. DU PONT DE NEMOURS AND COMPANY  
(Registrant)

Date: October 26, 2010

By: /s/Nicholas C. Fanandakis

Nicholas C. Fanandakis  
Executive Vice President and  
Chief Financial Officer  
(As Duly Authorized Officer and  
Principal Financial and Accounting Officer)

Table of Contents

EXHIBIT INDEX

Exhibit Number	Description
3.1	Company's Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the company's Annual Report on Form 10-K for the year ended December 31, 2007).
3.2	Company's Bylaws, as last amended effective November 1, 2009 (incorporated by reference to Exhibit 3.2 to the company's Annual Report on Form 10-K for the year ended December 31, 2009).
4	The company agrees to provide the Commission, on request, copies of instruments defining the rights of holders of long-term debt of the company and its subsidiaries.
10.1*	The DuPont Stock Accumulation and Deferred Compensation Plan for Directors, as last amended effective January 1, 2009 (incorporated by reference to Exhibit 10.1 to the company's Annual Report on Form 10-K for the year ended December 31, 2008).
10.2*	Company's Supplemental Retirement Income Plan, as last amended effective June 4, 1996 (incorporated by reference to Exhibit 10.3 to the company's Annual Report on Form 10-K for the year ended December 31, 2006).
10.3*	Company's Pension Restoration Plan, as restated effective July 17, 2006 (incorporated by reference to Exhibit 99.1 to the company's Current Report on Form 8-K filed on July 20, 2006).
10.4*	Company's Rules for Lump Sum Payments adopted July 17, 2006 (incorporated by reference to Exhibit 99.2 to the company's Current Report on Form 8-K filed on July 20, 2006).
10.5*	Company's Stock Performance Plan, as last amended effective January 25, 2007 (incorporated by reference to Exhibit 10.7 to the company's Quarterly Report on Form 10-Q for the period ended March 31, 2007).
10.6*	Company's Equity and Incentive Plan as approved by the company's shareholders on April 25, 2007 (incorporated by reference to pages C1-C13 of the company's Annual Meeting Proxy Statement dated March 19, 2007).
10.7*	Form of Award Terms under the company's Equity and Incentive Plan (incorporated by reference to Exhibit 10.8 to the company's Quarterly Report on Form 10-Q for the period ended March 31, 2009).
10.8*	Company's Retirement Savings Restoration Plan, as last amended effective January 1, 2009 (incorporated by reference to Exhibit 10.16 to the company's Quarterly Report on Form 10-Q for the period ended June 30, 2008).
10.9*	Company's Retirement Income Plan for Directors, as last amended August 1995 (incorporated by reference to Exhibit 10.17 to the company's Annual Report on Form 10-K for the year ended December 31, 2007).
10.10*	Company's Bicentennial Corporate Sharing Plan, adopted by the Board of Directors on December 12, 2001 and effective January 9, 2002 (incorporated by reference to Exhibit 10.19 to the company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2007).

## Edgar Filing: DUPONT E I DE NEMOURS & CO - Form 10-Q

### Table of Contents

<b>Exhibit Number</b>	<b>Description</b>
10.11*	Company's Management Deferred Compensation Plan, adopted on May 2, 2008, as last amended May 12, 2010 (incorporated by reference to Exhibit 10.11 to the company's Quarterly Report on Form 10-Q for the period ended June 30, 2010).
10.12*	Supplemental Deferral Terms for Deferred Long Term Incentive Awards and Deferred Variable Compensation Awards (incorporated by reference to Exhibit 10.15 to the company's Annual Report on Form 10-K for the year ended December 31, 2008).
12	Computation of Ratio of Earnings to Fixed Charges.
31.1	Rule 13a-14(a)/15d-14(a) Certification of the company's Principal Executive Officer.
31.2	Rule 13a-14(a)/15d-14(a) Certification of the company's Principal Financial Officer.
32.1	Section 1350 Certification of the company's Principal Executive Officer. The information contained in this Exhibit shall not be deemed filed with the Securities and Exchange Commission nor incorporated by reference in any registration statement filed by the registrant under the Securities Act of 1933, as amended.
32.2	Section 1350 Certification of the company's Principal Financial Officer. The information contained in this Exhibit shall not be deemed filed with the Securities and Exchange Commission nor incorporated by reference in any registration statement filed by the registrant under the Securities Act of 1933, as amended.
101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema Document
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	XBRL Taxonomy Extension Label Linkbase Document
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document

---

\*Management contract or compensatory plan or arrangement required to be filed as an exhibit to this Form 10-Q.